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1. INTRODUCTION 
 
Siddha system of  medicine  has virtually classified diseases into 4448 types on 
basis of the three humours ie, Vatham, Pitham,  Kabam constituting the fundamentals of 
this system. According to Classical Siddha literatures derangement of kabam can lead to 
21 different types of illnesses, of which Virana Silethumam is one of the disease. 
 The clinical picture of virana silethumam includes sore throat with mucous and 
pustular exudates, swelling of anterior and posterior cervical area with fever, rigor, 
burning sensation all over the body, cough, crying out of severity, ulceration of throat and 
tongue. The symptomatology of Virana silethumam  may be comparable with that of 
Acute Pharyngo-tonsillitis. 
 Around the world sore throat is one of the very common recurrent illnesses in 
children of which 37% being diagnosed as acute bacterial Pharyngo-tonsillitis1. It is a 
common condition nearly all children are becoming infected atleast once. Indian children 
are more prone to the risk of developing complications like rheumatic fever, acute 
glomerulonephritis due to the prevailing unhygienic conditions. About 80% of children 
with obstructive sleep apnoea are suffering from tonsillar hypertrophy2.  
 The initial management for infected tonsils in allopathic medicine is antibiotics. If 
frequent infections or trouble breathing occur tonsillectomy will be done.  Administration 
of antibiotics and analgesics to children have resulted in the development of higher 
Arora et al, 1999) and also  kill healthy 
intestinal bacteria which helps to keep the immune system healthy. 
Around 200,000 tonsillectomies are done annually in India which is the 
commonest surgical procedure in children. Tonsillectomy also has demerits children like 
post-operative haemorrhage, pain, nausea, vomiting etc.. 
2 
 
 
  This compels me to explore an efficacious anti-microbial drug which is purely 
herbal, adequately safe and easily available for pediatric population. The constituents of 
trial drug Coriandrum sativum, Cuminum cyminum, Nigella sativa possess antibacterial 
activity. Glycyrrhiza glabra  possess  anti-inflammatory and anti-allergic activity. Also 
the drug has essential oil containing predominantly derivative of Eugenol(Hattori et al 
1986), which act potently against 25 genera of bacteria (including Streptococcus, 
B.subtilis), some of which are involved in causing pharyngo tonsillitis (Ghelardini et al 
2007). 
 In our research, we have studied the clinical efficacy of the experimental 
formulation in children. The above said formulation ingredients are herbal origin only. 
Even though the drugs are pure herb, we have studied preclinical safety study. It shows 
that the formulation has potential anti-inflammatory activity clinically effective in the 
management of Virana Silethumam.  
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2. AIM & OBJECTIVES 
AIM 
 To study the efficacy of Malli chooranam for the management of Virana 
silethumam with reduction of clinical symptoms. 
 To ensure a combined approach of modern and siddha concepts for the 
clinical  diagnosis of the Virana silethumam. 
 
OBJECTIVES 
 To evaluate the Safety of Malli Chooranam by  Acute and  Sub acute 
Toxicity studies  in animal models. 
 To evaluate the Safety  and Efficacy of Malli Chooranam in pediatric 
population.. 
 To study the subjective changes of  
 Udal kattugal,  
 Ennvagai Thervu and  
 Mukkutram in patients with Virana silethumam. 
 To elucidate the correlative aspects of Virana silethumam and Acute      
Pharyngo-tonsillitis in terms of clinical manifestations. 
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3. REVIEW OF LITERATURE 
SIDDHA ASPECTS 
The term Virana silethumam, etiology and clinical manifestations is briefed in 
Siddha maruthuvam- Pothu text. Information regarding various features was collected 
from other Siddha literatures. 
 
­Âø (DEFINITION) : 
Accumulation of phlegm in the throat, chest leads to derangement of kabam, 
pitham in areas of throat, nose, tonsil producing inflammation and exudation of mucus, 
phlegmatic secretions from these regions. 
 
§ÅÚ ¦ÀÂ÷¸û (SYNONYMS): 
 
¦¾¡ñ¨¼ìÌÕ  -Thondai Kuru3 
¦¾¡ñ¨¼ì¸ðÎ   -Thondai Kattu5 
¦¾¡ñ¨¼ ¸Àõ   -Thondai Kabam5 
¦¾¡ñ¨¼ì ¸¢Ãó¾¢ Å£ì¸õ -Thondai Kirandhi veekam4 
¦¾¡ñ¨¼Â¢ø ÅªÕõ º¨¾-Thondail Valarum sathai6 
ÌÃü¸õÁø    -Kural Kammal5 
¸ª À¢Õó¾õ    -Kala Biruntham5 
¸ª ÅíÌÃõ    -Kala Vanguram5 
¸ª ÍñÊ   -Kala Chundi5              
¸ñ¼ì ¸¢Ãó¾¢   -Kanda Kiranthi5 
¸ñ¼ ºóÐ §Ã¡¸õ  -Kanda Santhu rogam5 
¸ñ¼ º¡æ¸õ    -Kanda Salugam5 
¸ñ¼ ÍñÊ   -Kanda Sundi5 
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§¿¡ö ÅÕõ ÅÆ¢ (ETIOLOGY):  
Exposure to cold air, excessive eating, frequent intake of sweet and sour taste 
foods, tubers, previously cooked rice and climatic extremes in the month of masi, 
panguni will lead to excessive accumulation of Iyam. 
According to Pillai Pini maruthuvam
throat is caused by  
 Poor health condition of mother 
 Playing in cold water, 
 Frequent eating of cold food items, 
 Exposure to cold air, 
 Poor nutritional condition of the child. 
 
 
 Å¡Õ§Á Å¢Ä¡× ¦¿ïÍ ÁÕÅ¢Â ¯ÚôÒ ¾ýÉ¢ø 
¿£Õ§Á ¯¨ÈóÐ ¸ÀÓõ ¿¢ýÈÐ ÅÈðº¢Â¡¸¢ 
  
(º¢Ãº¢Ä¢ÕóÐ ÌÅÎ, ¦¾¡ñ¨¼, Å¢Ä¡×, ¦¿ïÍ Ó¾Ä¢Â ¯ÚôÒ¸ª¢ø ¯¨Èó¾ 
¸Àõ ÅÈðº¢Â¡¸¢ ÌÆó¨¾¸û ¯¼Ä¢ø ¿£Ã¡¸ «¼Õõ). 
 
In Kuzhandaigal noigal part-V, it is said that kabam condensed in areas of head, throat, 
and chest gets dried further spreading in fluid nature throughout the body 
Due to inattentive parental care, concerning actions of child there can be an 
exacerbation of the phlegm in the chest and others regions. 
 
¦º¡øÄ¢Â ¦ºýÉ ÜüÈ¡ø Ð¼÷ ÀÆÅ¢¨ÉÂ¡ø ÅóÐ 
  
«øÄ¸º¢Ãº¢ø ¿£Ã¡ø «ý¨ÉÂ¢ý À¡Ä¢É¡Öõ 
 ¸øÄ¸ ¿ÃõÀ¢ø ¾¡Å¢ ¸ÀÁÐ ÅóÐ º¡Õõ...  
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Previous karmic deeds, thosham of the organs, excessive water in regions of head, 
children as told in the above poem taken from Kuzhandaigal noigal part-V. 
 
§¿¡ö ±ñ (CLASSIFICATION): 
 
According to Siddha Maruthuvam Pothu, there are 21 types of Silethumam 
ailments and Virana silethumam is one among them. 
 
ÓüÈ¡É º¢§ÄðÁó ¾¡É¢ÕÀò ¦¾¡ýÚ 
   ÓÉ¢Ô¨Ãò¾ ¦º¡üÀÊ§Â ¦Á¡Æ¢Âì §¸ª¡ö 
º¢üÈ¡É Å¢ÕÁÄ¡ó º¢§ÄðÁò §¾¡Î 
   ¦ºÈ¢¸¡ºî º¢§ÄðÁÁ¡ï ÍÅ¡ºî º¢§ÄðÁõ 
ÁüÈ¡É ¾£ÀÉº¢ §ÄðÁò §¾¡§¼ 
   Áó¾º¢§Äð ÎÁÅ¡¾ º¢§ÄðÁ Á¡Ìõ 
ÐüÈ¡É À¢ò¾º¢§Äð Áó¦¾¡ó¾ º¢§ÄðÁï 
   Í¸ºýÉ¢ Å¡¾º¢§Äð ÎÁó¾¡ É¡§Á. 
¬Ì§Á ÍÃº¢§ÄðÁ Á¾¢º¡Ã º¢§ÄðÁ 
   Á¾¢¸ºÄ º¢§ÄðÁÁ¡ Áì¸¢É¢ º¢§ÄðÁõ 
§À¡Ì§Á â¾º¢§ÄðÎÁ ÓÂÄ¸ýÈ¡ý 
   ¦Á¡È¢¦ÅÈ¢î º¢§ÄðÁÁ¡õ Å¢¸¡Ã º¢§ÄðÁõ 
§º¡ÌÍ§Ã¡ ½¢¾º¢§ÄðÁõ Å¢Ã½ º¢§ÄðÁó 
   Ð÷¸ó¾ º¢§ÄòÁÁ¡ ¿¢ò¾¢Â º¢§ÄðÁõ 
¿¡Ì§Á ­ÕÀò¦¾¡ý È¡ïº¢ §ÄðÁõ 
   ¿¡ðÊ§Éý ÅÃÄ¡Ú ¿ÂóÐ §¸§ª.    
          - ä¸¢ º¢ó¾¡Á½¢ 
7 
 
The 21 types of Silethumam are as follows: 
1)Irumal 2) Kasam 3) Swasam 4) Theebanam 5) Mantham 6) Vali 7) Azhal 8) 
Mukkoottu 9) Sugasanni  10) Suram 11) Athisaram 12) Neerkovai 13) Anal 14) Pootham  
15) Muyalagan 16) Veri 17) Vigaaram 18) Suronitham 19) Viranam 20) Thurkandham 
21) Nithtiyam. 
 
ÓìÌüÈ §ÅÚÀ¡Î¸û (PATHO-PHYSIOLOGY):  
 
¦¾¡ñ¨¼¦ÂýÀ¢ý ºó¾¢ ¿¢Èõ §º¡üÚô¨À ¿¡º¢¾¨Ä 
 ´ñ¦¼¡Ê§Â ÅÁò ÐªÀ¢ò¾ò ¦¾¡ñ½£÷î 
ÍÃôÀ¢ Â¢Ãº¾¡Ð Íò¾ ¿¢½õ ¿¡×õ 
 ¾ÃÁ¡É ¨ÅÂò ¾¢¼õ. 
  - ÁÕòÐÅ ¾É¢ À¡¼ø 
Head, throat, chest, nose, tongue, rasa thathu are main sites of Kapham. It is 
responsible for the secretory and lubricatory functions of these organs. The chemical 
changes that takes place alongside; underline the synergy of pitham in maintaining 
healthy secretory mucosal lining of the sites of kapham. (Siddha Maruthuva Sudar) 
 
TV.Sambasivam pillai Dictionary) cause  
 
1. Derangement of Kapham in first place followed by  
2. Derangement of Pitham producing an inflammatory reaction of the lining seretory 
mucosa. 
3. Inorder to excrete the exudative secretions produced, body initiates a sequelae of 
response leading to morbid condition, Virana Silethumam. 
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§¿¡ö ÌÈ¢ Ì½í¸û (CLINICAL FEATURES): 
¾¡¦ÉýÈ ¦¾¡ñ¨¼Â¢É¢ü ÒñÏ Á¡¸¢î 
   ºª¢§Â¡Î º£ò¾¡Ðí ¸ÄóÐ Å£Øí 
¸¡¦ÉýÈ ¸Øò§¾¡Î À¢¼Ã¢¸ýÉí 
   ¸ÉÁ¡¸ Å£í¸¢§Â ¸¡öîº Öñ¼¡í 
§¸¡¦ÉýÈ Ìª¢§Ã¡Î ±Ã¢×ñ ¼¡Ìõ 
   ¦¸¡ì¦¸ýÈ ­ÕÁ¢§Â ÜÅ Öñ¼¡õ 
§Å¡¦ÉýÈ Á¢¼¦ÈøÄ¡õ ¿¡×õ Òñ½¡ 
   Á¢¸ Å¢Ã½ º¢§ÄðÁò¾¢ý Å¢ÅÃó ¾¡§É. 
- ä¸¢ º¢ó¾¡Á½¢ 
According to the above poem in Siddha maruthuvam-pothu, the clinical 
manifestations are as follows: 
 Ulceration of throat with exudation of mucosal, pustular exudates 
 Swelling in neck, nape of neck and cheek accompanied by fever, rigor 
 Burning sensation in the body 
 Cough, crying out of severity of pain 
 Ulcerations of throat and tongue. 
 
Siddha terminologies specifically related to & in support of Virana silethumam 
was found to be in Tamil-English Dictionary by TV.Sambasivampillai. They are,  
 Silettuma vali: body ache caused by deranged kapham 
 Sileshma thalaivali: A kind of headache in which the palate and the throat 
secretion to be covered with a coat of sticky mucus with a feeling of cold and 
heaviness of head, which cannot be turned about. 
 Kanda suram: fever caused by deranged kapham. 
 Kanda sosham: dryness of throat 
 Kanda soolai: pricking pain  in throat due to disease of throat glands. 
 Kanda peedam: sharp/acute pain in the throat. 
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À¢½¢ «È¢Ó¨È¨Á (DIAGNOSIS): 
 
«ð¼Á¡í¸¢Ã¢ ¸¼ý¨É ÂÈ¢óÐ ¿£Ô½Ã§Å 
 Åð¼Á¡Ó¸í¸û ÀøÖ¸ Å¡Â¾¢ø ¿¡ìÌí¸¡Âí 
 ¸ð¼ÕÁÄí¸û ¨¸¾É¢ø ¿¡Ê¾¡Ûó 
 ¾¢ð¼Á¡ÂÈ¢óÐ ¦ºöÔó ¾¢ÈÓûª ÅÂ¢ò¾¢ÂÃ¡§Á. 
(«¸ò¾¢Â÷ ¬Ôû §Å¾õ-1200). 
Since infants and young children may not be correctly able to explain symptoms, 
diagnosis of diseases depend upon the sharp analytical capability of physician. According 
to BalaRoga nithaanam, Kashyaba samhitai, mild rise in temperature, distaste, 
excessive salivation, inability to swallow it may be enough in diagnosing a throat disease. 
 
Piniyari muraimai  The method of diagnosing in Siddha is based upon  
parts of the patients) 
disease).  
3. Vinathal (asking informations regarding the history of the disease, its 
clinical feature etc., from the patient or his close relatives who are taking care of 
him). 
4. Ennvagai thervugal (eight fold examination). 
 
The above principles correspond to the methodology of  
(a) Inspection, (b) Palpation and (c) Interrogation as in modern medicine.  
, first three are very 
significant and useful in examination of a patient. They are,  
1. Kaandal: (Inspection by Siddha method)   
2. Karuthal: (Through Siddha Investigations)  
3. Urai: (Literature reference of Siddha system)  
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 ±ñ Å¨¸ò §¾÷× (EIGHT-FOLD EXAMINATION): 
 
 
 ÁÄõ ãò¾¢ÃÁ¢¨Å ÁÕòÐÅ Ã¡Ô¾õ." 
  - º¢ò¾ ÁÕòÐÅ §¿¡ö ¿¡¼ø §¿¡ö Ó¾ø ¿¡¼ø ¾¢ÃðÎ 
"¦ÁöìÌÈ¢ ¿¢Èõ ¦¾¡É¢ Å¢Æ¢ ¿¡ ­ÕÁÄõ ¨¸ìÌÈ¢" 
- §¾¨ÃÂ÷. 
 
This is an important part of diagnosis as framed by siddhars. This includes, 
1.  (Sensation to touch)  
2. ¿¡ (Tongue)  
3. ¿¢Èõ (Colour)  
4. ¦Á¡Æ¢ (Voice)  
5. Å¢Æ¢ (Eyes)  
6. ÁÄõ (Faeces)  
7. ãò¾¢Ãõ (Urine)  
8. ¿¡Ê (Pulse) 
 
1.  (Sensation to touch): 
Sparisam is a method of palpation and percussion to know the condition of the 
body like warm, fever, chillness, sweating, numbness, paresthesia, dryness of the body, 
erosion patches, ulcers, edema, emaciation, swelling, obesity and enlargement of liver, 
spleen.  
In Virana silethumam, there is 
 Swelling in the cervical region 
 Warmth in areas of swelling 
 Pain in the areas of swelling 
 Fever  
 Dryness of skin 
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2. ¿¡ (Tongue) : 
This is the method of inspection of the tongue mainly gums, teeth, lips, palate etc. 
In Virana silethumam, 
 Whitish nature of the tongue with coating and pallor was observed indicating 
the derangement of Silethumam. 
 Soreness at the edges of the tongue during fever indicating aggravation of 
pitham. 
 
3. ¿¢Èõ (Colour) : 
Colour (indicating the vatham, pitham, kabam, mukkutram) yellow, pallor, 
redness of the skin and colour of nail beds are noted. In Virana silethumam, pallor of skin 
will be present as it is one of the kabam ailments. 
 
4. ¦Á¡Æ¢ (Voice): 
 Clarity of voice, any disturbances in speech, loud voice, slurring, crying, talk 
induced by hallucination are noted. In Virana silethumam, voice disturbances are due to 
sore throat and hoarseness of voice. Difficulty in speaking is due to excessive pain in 
swallowing the saliva. 
 
5. Å¢Æ¢ (Eyes) : 
Abnormal colour changes indicate the three thodams. Pallor, excessive 
lacrimation, accumulation of secretion at the angle of eyes, subconjunctival bleeding, and 
any specific diseases in the eyes are noted. In Virana silethumam, pallor of conjunctivae 
is present. In few, there is diffuse congestion of the conjunctivae due to continuous 
cough. 
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6. ÁÄõ (Faeces) : 
 
ÁÄãò¾¢ÃìÌÈ¢ ¦ºôÀ¢Êý Á¨Ä§ÁüÀÌ¾¢ Å¢ªì¸¡õ 
¨ÁÂü¦¸¡Î ¸¨½Â¡¸¢Â ¦ÁªÅó ¾¢¨½Â¡§Á 
ÁÄÁ¡ÉÐ ÒÂÄ¡¦ÁÉ¢ü ÁýÉ¢ü ¦ÀÚÍÃ§Á 
ÁÄÕí ¸Å¢ÈÉª¡ø ¾ýÁì¸û ¦ÀÚÍÃ§Á 
Á¸Å¡ý ¸Ã¢Â¡É¡ ÅÐ ÁÈÅ¢ý ÍÃÁ¡§Á 
Áïºð¸¢¨½ Â¡ÉÅÐ Áñ½¢ü ¦¾¡Î ¸À§Á. 
    ddddddddd- §¾Ãý ¨Åò¾¢Â Á¸¡ ¸Ã¢ºø. 
 
Quantity, colour, odour, frothy, consistency, indigestion, frequency are noted. 
Few patients had, reduced frequency of defecation and passing of hard stools. 
 
7. ãò¾¢Ãõ (Urine) : 
Quantity, colour, odour, frothy, frequency, retention, deposits, presence of 
abnormal constituents is noted. 
 
¿£÷ìÌÈ¢: 
 
"Åó¾ ¿£÷ì¸Ã¢ ±¨¼ Á½õ  Ñ¨Ã ±ïº¦Äý 
 ¨Èó¾¢Â Öª¨Å Â¨ÈÌÐ Ó¨È§Â" 
   -º¢ò¾ ÁÕòÐÅ¡í¸î ÍÕì¸õ. 
The following are observed: 
1. Niram - Colouration  
2. Edai - Specific gravity  
3. Manam - Smell  
4. Nurai - Frothy Nature  
5. Enjal - Quantity of urine voided.  
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¦¿öìÌÈ¢: 
 
The diagnosis and prognosis of Muthodam, derangement of the disease are 
studied on the basis of behaviour by drop of gingelly oil on the surface of the urine kept 
in a wide vessel in the sunlight. 
 
The collected specimen as said above is to be analyzed by following method. The 
specimen is kept open in a glass dish. It is to be examined under direct sunlight, without 
any shaking of the vessel. Then add on drop of gingelly oil by at distance of ½ or ¾ 
height, observe keenly the direction in which it spreads within few minutes, and conclude 
the diagnosis as follows, 
 
''«Ã¦ÅÉ ¿£ñÊý «·§¾ Å¡¾õ 
¬Æ¢§À¡ø ÀÃÅ¢ý «·§¾ À¢ò¾õ 
Óò¦¾¡òÐ ¿¢ü¸¢ý ¦Á¡Æ¢Å¦¾ý ¸À§Á.'' 
 
If the oil droplet spreads like snake it signifies, vatham; if it spreads like a ring it 
shows pitham aggravation. The droplet is static as  pearl in Kapham derangement. 
 
8. ¿¡Ê (Pulse): 
 
 
ÐÄì¸ÓÈõ ÀñÊ¾§Ã ¦¾ª¢Å¡¸ô 
ÀÌì¸Ã¢Â ¿¡Ê¨Â ¿£ ÀÊòÐ À¡Õô 
À¸÷¸¢ýÈ Å¡÷ò¨¾¨Âô À¡÷ ¿¡¨Åô À¡Õ 
ÅÌì¸Ã¢Â §¾¸¦ÁÉò ¦¾¡ðÎô À¡Õ 
ÅªÁ¡É ºÃ£Ãò¾¢ý ¿¢Èò¨¾ô À¡Õ 
º¸¢ì¸Ã¢Â ÁÄò¨¾ô À¡÷ ºÄò¨¾ô À¡Õ 
 
  -«¸ò¾¢Â÷ ¨Åò¾¢Â ÅøÄ¡¾¢ 600   
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Naadi is a suitable diagnostic tool used by siddhars from the unknown past. It can 
be felt one inch proximal to the wrist on the radial side by means of palpation with the tip 
of index, middle and ring fingers corresponding vatham, pitham and Kabam respectively. 
The three humours Vatham, Pitham and Kabam exits in the ratio 1:1/2:1/4 normally.  
 
Any derangement in the ratio produces disease as in Thirukural, 
''Á¢¸¢Ûõ Ì¨ÈÂ¢Ûõ §¿¡ö ¦ºöÔõ Åª¢ 
Ó¾Ä¡ ±ñ½¢Â ãýÚ ''.  
 
Examination of the Naadi has been recognized as one of the principle means of 
diagnosis. But Naadi is not much used for the pediatric diagnosis because considering the 
physical conditions of the child; naadi can not be understood correctly in children. It is 
stressed by Siddha maruthuva chudar following Sathaga naadi verse, 
 
"¦¸¡ñÊ¼§Å ¸Â§Ã¡¸¢ ¸¡º §Ã¡¸¢ 
ÌÈ¢ôÀ¡¸î º¢üÈ¢ýÀõ ¦ºö¾ §À÷¸û 
«ñÊ¼§Å ¾Ã¢ò¾¢Ã÷¸û Å¢Õò¾÷ À¡Ä÷ 
«ýÀ¡¸ò ¾ñ½£Ã¢ø ãú¸¢§É¡÷¸û 
¦¸¡ñÊ¼§Å ­Å÷¸ªÐ ¯ÚôÀ¢ý ¾¡Ð 
ÜÈ§Å ÓÊÂ¡Ð ±Å÷ìÌì ¸¢ðÎõ 
ÀñÊ¼§Å Â¢ôÀÃ£ð¨º Â¡÷¾¡ý ¸¡ñÀ¡÷ 
ÀÃ¡ÀÃò¾¢ý Á¸¢¨ÁÂ¢Ð À¡Õ À¡§Ã"  
   -º¾¸ ¿¡Ê. 
 
However, it is always worth trying to assess Nadi in children when it was quite 
apprehendable. In cases of Virana silethumam, vatha pitham was apprehended commonly 
followed by Pithakabam and kaba pitham. It correlates with Paripurana Nadi as follows, 
 
"Å¢Ã½Ó¼ý Òñ Ò¨ÃìÌ Å¡¾À¢ò¾õ" 
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 ÓìÌüÈ §ÅÚÀ¡Î¸û (Tri-humoral Derangements): 
 
It is the derangement of three vital Humors (ie) Vatham, Pitham and Kabam. 
 
1. Å¡¾õ (Vatham)  
Vatham is a kinetic energy influencing all movements, located in the 
abanan, idakalai, faeces, spermatic cord, iliac bone, skin, nerves, joints, hair 
follicles, muscles, bone, ear and thigh. 
 
 
S.No Name Locations Physiologic Functions 
 
1 
 
Piranan 
 
Heart and Lower 
and Upper 
Respiratory Tracts 
 
Controls knowledge, mind and five 
objects of sense, useful for breathing 
 
2 
 
Abanan 
 
Lower abdomen 
and extremities 
 
Responsible for urination, expels 
faeces and foetus, discharge of 
sperm and menstruation. 
 
3 
 
Viyanan 
 
Mainly at heart 
 
Responsible for movement of all 
parts of the body and used to feel the 
sensation 
 
4 
 
Uthanan 
 
Chest 
 
Responsible for vomiting, cough, 
hiccough, sneezing 
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5 
 
Samanan 
 
Stomach 
 
Aids for proper digestion. It controls 
the activity of other vayus 
 
6 
 
Naagan 
 
Eyes 
 
Responsible for opening and closing 
of the eyes 
 
7 
 
Koorman 
 
Heart and Eyes 
 
Responsible for vision and yawning 
and controls lacrimation 
 
8 
 
Kirukaran 
 
Throat 
 
Responsible for salivation nasal 
secretion and appetite 
 
9 
 
Thevathathan 
 
Eruvai & Karuvai 
 
For laziness, sleeping and anger 
 
10 
 
Thananjeyan 
 
Nose 
Responsible for bloating of the body 
after death. It escapes on the third 
day after death through the cranium 
when it bursts. 
 
In Virana silethumam, the following are affected, 
1. Uthanan: cough, sore throat , difficulty to swallow 
2. Samanan : poor control of other vayus  
3. Kirukaran : poor appetite, nasal secretion,  
4. Devathathan: malaise, sleepiness 
5. Abanan : constipation, passing of hard stools 
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2. À¢ò¾õ (Pitham):  
Pitham is the Fuelling energy located in urinary bladder, heart, head, 
umbilicus, abdomen, blood, sweat, skin and eyes. Pitham is classified into 5 types.  
 
They are,  
 
1. Anal Pitham - Responsible for the digestion of food.  
2. Ranjaga pitham - Responsible for the colour of blood. 
3. Sathagam - Located in heart and is responsible for normal activities of the 
body.  
4. Alosagam - Responsbile for normal vision  
5. Prasagam - Responsible for the complexion of skin.  
 
In virana silethumam, the following can be affected 
1. Analam  poor appetite 
2. Renjagam  pallor of body, conjuctiva , nail bed  
 
3. ¸Àõ (Kabam):   
 
It is the restorative energy that stabilizes, maintains and lubricates all 
organs. Kabam is found in samanan, semen, brain, head, tongue, nose, bones, 
bone marrow, fat, nerves, chest, blood, large intestine, eye, stomach and pancreas.  
 
Kabam is classified in to 5 types, they are,  
1. Avalambagam : Heart is the center for Avalambagam, It controls all other 
forms of kabam.  
2. Kilethagam : Stomach is the center for kilethagam. It gives moisture and 
softness to the ingested food and helps for digestion.  
3. Pothagam : Tongue is the center for pothagam and it is responsible for  the 
sense of taste.  
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4. Tharpagam : Head is the center for tharpagam. It gives cooling effect to 
eyes.  
5. Santhigam : It lies in the joints and is responsible for the locomotive action 
of movable bony joints. 
 Sometimes, pothagam may be affected producing distaste in silethuma diseases. 
 
¯¼ü¸ðÎ¸û (7 Physical Constituents):  
Udal Kattugal are 7 in number as follows, 
 
1. Saaram : It is the final product of the digestive process, which gives strength 
to the body and mind.  
2. Senneer : Saaram after absorption is converted into senneer. It is responsible 
for knowledge, strength, boldness, and healthy complexion.  
3. Oon : Gives structure and shape to the body and is responsible for the 
movement of the body.  
4. Kozhuppu : Lubricates the organs and proceed on it own works.  
5. Enbu : Protects the vital organs and used for movements and nominates the 
body structure.  
6. Moolai : Present inside the bones and it gives strength and maintain the 
normal condition of the bone.  
7. Sukkilam/Suronitham : Responsible for the reproductive functions of the 
species.  
 
In Virana silethumam, Saaram is affected in all patients and Senneer is affected in  
some of the patients. 
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ÀÕÅ¸¡Äõ (Seasonal Variations): 
The whole year is constituted by six seasons. They are, 
 
S.No Kaalam Kuttram State of Kuttram Suvai 
1 Kaar Kaalam 
(Aavani-
Puratasi) 
(Aug16  Oct 
15) 
 
 
 
Vettrunilai Valarchi. 
 
Thannilai Valarchi 
 
 
Enippu 
Pulippu 
Uppu. 
 
2 Koothir 
Kaalam 
Iypasi  
Karthigai 
(Oct16  
Dec15) 
 
 
 
 
Thannilai Adaithal. 
 
Vettrunilai Valarchi. 
Enippu 
Kaippu 
Thuvarppu 
 
3 Munpani 
Kaalam 
( Markazhi  
Thai) 
(Dec16  
Feb15) 
 Thannilai Adaithal Enippu 
Pulippu 
Uppu 
 
4 Pinpani 
Kaalam 
(Masi  
Panguni) 
(Feb16  
Apr15) 
 Thannilai Valarchi. Enippu 
Pulippu 
Thuvarppu 
20 
5 Elavenil 
Kaalam 
(Chithirai  
Vaikasi) 
(Apr16  
Jun15) 
 Vettrunilai Valarchi. Kaippu 
Karppu 
Thuvarppu 
6 Mudhuvenil 
Kaalam 
(Aaani  
Aadi) 
(Jun16  
Aug15) 
 
 
 
 
Thannilai Valarchi 
 
Thannilai Adaithal 
 
Enippu 
 
- - - Thannilai Adaithal . 
 
The incidence of viranasilethumam is predominant in Koothir kaalam and Munpani 
Kaalam. But also occurs in other kaalam, because of life style modification.  
 
According to silethuma roga ilambagam, kabam 
 Starts to increase in masi, panguni 
 Overflows from actual sites to spread in aadi, aavani, purattasi. 
 Reaches its maximum during vaigasi. 
 
³ó¾¢¨½ (FIVE TYPES OF LANDS):  
It is divided into five types.  
1. Kurinji : Mountain regions and surroundings.  
2. Mullai : Forest regions and surroundings.  
3. Marutham : Cultivating regions and surroundings.  
4. Neithal : Sea and Coastal regions.  
5. Palai : Desert land only.  
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In Kurinji nilam kaba disease are common. In Palai nilam all disease can be 
caused by deranged vatha, pitha and kaba thodam. Pitha diseases are widely seen in 
Mullai nilam. Virana silethumam can occur in any nilam since  the dietary patterns and 
habits of the patients can vitiate the Kaba thathu.  
 
 ¯¼ø Åý¨Á (Body Immunity): 
Smartness, strength and vitality constitute Udal Vanmai. It is classified into 3 types as 
 
1. Iyarkai Vanmai:  
Natural immunity of the body itself by birth.  
2. Seyarkai Vanmai:  
Improving the health by intake of nutritious food materials, activities and 
medicines.  
3. Kaala Vanmai:  
Development of immunity according to age and the environment.  
 
The Vanmai of the children plays an important role in causing the disease and 
pregnancy, in addition to intake of unwanted foods, unhealthy habits by the child and 
climatic changes. 
 
 ÁÕòÐÅõ (Treatment): 
 
 
ÁÕó¾Ð º¾Í§Ä¡¸¢ ¿¢¸ñÊÉ¢ø ÅÌò¾¡÷ Óý§É¡ 
Ã¢Õó¾¢Îï º¢§ÄüÀÉò¾¢ É¢ÉÁÈ¢ó¾ÕóÐÅ£§Ãü 
 
       -¾ýÅó¾¢Ã¢ ¨Åò¾¢Âõ 
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The author of the poem recommends that all types of silerpana rogams can be 
cured if the each type is treated with appropriate medicine after knowing the exact nature 
of illness.  
Siddha treatment is not only for complete healing but also prevention and 
rejuvenation. The three facets of a vital Siddha therapy involves the following: 
 
1. ¸¡ôÒ - Prevention:  
treating a disease. Emulation of healthy diet pattern with sattvic foods, daily habit forms, 
growth and immunity is essential. This forms 
the basis of parental counselling to strengthen the seyarkai vanmai of the child to prevent 
detoriation of host immune response to microbial invasion as in case of Virana 
silethumam. Developing awareness among mothers regarding preventive aspects 
facilitates reduction in incidence of silethumam diseases among pediatric population. 
 
Prevention methods:  
 To avoid chill and cold weather.  
 To dress according to weather conditions. 
 To avoid eating outside frequently. 
 To avoid cold food stuffs, ice creams, etc.  
 To avoid contaminated food and water.  
 To avoid unhealthy habits like nail biting, thumb sucking, pica etc. 
 To find out which agent makes allergy and avoid them.  
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2. ¿£ì¸õ  Treatment: 
Line of Treatment:  
The line of treatment as suggested by PillaiPini Maruthuvam states: 
To neutralize the vitiated Kapham and remove phlegmatic secretions, 
 Expectorant 
 Stimulants 
 Anti-spasmodics can be given. 
To relieve fever, sore-throat and headache, 
 Febrifuge 
 sedatives 
 Diaphoretics 
 Demulcents can be used. 
Siddhars ideology proves meticulous combinations of dry and heat charachters 
with silethumam can neutralise the deranged kabam. This helps in curing grave diseases.  
 
Anupanam in Siddha system:  
 
 
­É¢¾¡É ÍìÌ ¸ýÉø  ­ïº¢ - À¢ÛÓ¾¸í 
§¸¡ÁÂõ À¡øÓ¨ÄôÀ¡ø §¸¡¦¿ö§¾ý ¦ÅüÈ¢¨Ä¿£÷ 
 
     -§¾¨ÃÂ÷ ¦ÅñÀ¡. 
 
Anupanam (Thunai marunthu) is considered vital in siddha without which there 
cannot be success in treatment. According to dictionary of TVS, vehicle employed goes 
to modify the quality or active principle of the medicine itself, thus rendering the potency 
and curative power consistent  with the nature of the disease for which it is administered. 
This point goes synchronous with milk  in treating silethuma ailments 
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Pathiyam:  
Pathiyam comprises a list of dietary, habitary pattern that has to be followed to 
equalize the deranged kuttrams and the restrictions help in enhancement of drug action in 
addition to favouring quick recovery from the illness. 
 
For patients of kabam disorders, the following are suggested. 
 
 
«ò¾¢ì ¸¡ö¸Ùõ ÅÕì¨¸Á¡ÀÂ¢ü¨È Í¨ÃÂ¡ø À£÷ì¸Õõ-À¢ïÍ§Å÷ 
¦Á¡öò¾ ÝÃ½í ¸¾Ä¢ò ¾ñÎ¸¨ªô âÓªí¸¢ ÓÕì¸ÕõÒõ 
«ò¾¢ô âº¢É¢ì ¸¡ÂÕûª¢ Åûª¢Ôí ¸Àò§¾¡÷ì ¸¡½Á¡§Á. 
§Å¨ª Á½ò¾ì¸¡ª¢ ¦Áý º£¨¾ ºìÃÅ÷ò¾¢ 
À£¨ª Åº¨Ä ÍìÌ ¦ÀñÍ½í¸û-§Å¨ªÂ¢¨Ä 
¦ºó¾ª¢÷ ¸¨ªì £¸¨Ã ¦ºöÅ÷ ¸À§¾¸÷ ¿¢¾õ 
 
   -À¾¡÷ò¾ Ì½ º¢ó¾¡Á½¢. 
 
Diet Restriction:  
 Avoidance of  cold drinks, cold food items, cold water, sour fruits like sapota, 
banana, oranges, lemon, sweet lime , grapes, watery veggies were advised. 
 Intake of hot milk with turmeric, pepper and palm candy at nights advised. 
 Intake of one among ginger, pepper, thoothuvelai, karisalanganni and 
manathakkali leaves as rasam, curry, thuvayal or adai was recommended. 
 In non-vegetarians, intake of certain varieties of fish, field crab and mutton 
liver soup were advised. 
 In addition, intake of timely, hot easy digestible foods was stressed.  
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3. ¿¢¨È× (Restoration): 
 Reassurance of disease recovery was given to all patients.  
 The children and their parents were advised to follow the essential elements of 
Siddha dietary, habit pattern and preventive methods to ensure that the illness 
does not recur.  
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MODERN ASPECTS 
 
TONSILS AND ADENOIDS 
  
ANATOMY: 
The tonsils are pairs of soft tissue masses located at the rear of the throat 
(pharynx). Each tonsil is composed of tissue similar to lymph nodes, covered by pink 
mucosa (like on the adjacent mouth lining). Running through the mucosa of each tonsil 
are pits, called crypts. 
WALDEYER RING: 
There are superficial masses of lymphoid tissue in the pharyngeal mucosa, which 
form a ring that acts as a filter, protecting the body against infecting organisms that might 
enter it from the nose or mouth. This ring of lymphoid tissue surrounding the oral and 
nasal openings into the pharynx is called "Waldeyer's Ring". It includes   
1) Palatine tonsil  
2) Pharyngeal tonsil/ adenoid 
3) Lymphoid tissue surrounding Eustachian tube orifice into the lateral walls of 
the naso pharynx. 
4) Lingual tonsil at the base of the tongue 
5) Scattered lymphoid tissue throughout the remainder of the pharynx but 
especially behind the posterior pharyngeal pillars and along the posterior 
pharyngeal wall. 
 
PALATINE TONSIL:  
Lymphoid tissue located between the palato-glossal fold (anterior tonsillar pillar) 
and the palato pharyngeal fold (posterior tonsillar pillar). This is separated from the 
surrounding pharyngeal musculature by a thick fibrous capsule. 
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ADENOID:  
Single aggregation of lymphoid tissue occupies the space between the nasal 
septum and the posterior pharyngeal wall. A thin fibrous capsule separates it from the 
underlying structures. Adenoid does not contain complex crypts that are found in the 
palatine tonsils but rather simpler crypts. 
LINGUAL TONSIL:  
Lymphoid tissues at the base of the tongue contain simpler tonsillar crypts. 
 
PHYSIOLOGY: 
Approx 65% of the lymphocytes that make up for the Waldeyer Ring are B-
Lymphocytes, the remainder being either T-Lymphocytes or plasma cells. 
The immunologic role of the tonsils and adenoid is to induce secretory immunity 
and to regulate the production of secretory immunoglobulins. Situated at the opening of 
the pharynx to the external environment, the tonsils and adenoid are in a position to 
provide primary defense against foreign matter. The Deep crevices within tonsillar tissue 
form tonsillar crypts that are lined with squamous epithelium but have a concentration of 
lymphocytes at their bases. Lymphoid tissue of Waldeyer Ring is most immunologically 
active between 4 and 10 years of age, with a decrease after puberty. 
Recent studies have indicated the existence of an active cellular defence in the 
secretion on the tonsillar surface. This defence seems to consist partly of physiologically 
active neutrophils and is present in health and during disease.  
 
 NORMAL FLORA OF MOUTH AND UPPER RESPIRATORY TRACT: 
The mouth contains a plethora of organisms-pigmented and non-pigmented 
micrococci, some of which are aerobic, Gram positive aerobic spore bearing bacilli, 
coliforms, proteus and lactobacilli. The gum pockets between the teeth and the crypts of 
the tonsils have a wide spectrum of anaerobic flora  anaerobic micrococci, 
microaerophillic and anaerobic Streptococci, Vibrios, Fusiform bacilli, Corynebacterium 
species, Actinomyces, Leptothrix, Mycoplasma, Neisseria hemophilus, Branhamalla and 
28 
 
Bacterioides are all found in varying extents. Among fungi, Candida and Geotrichum 
have been reported. 
 
The mouth of the infant is not sterile at birth. It generally contains the same types 
of organi
These organisms diminish in number during the first 2-5 days after birth and are replaced 
by the types of bacteria present in the mouth of the mother and nurse.  
 
Within 12 hours after birth alpha hemolytic streptococci are found in the upper 
respiratory tract and become the dominant organisms of the oropharynx and remain so for 
life. In the pharynx and trachea, flora similar to that of mouth establishes themselves. 
Few bacteria are found in normal bronchi. Smaller bronchi and alveoli are normally 
sterile. 
The commensals from the normal flora of the mouth, nasopharynx may get into 
the blood and tissues. They are usually quickly eliminated by the normal defence 
mechanism of the body; occasional diphtheroids or non-hemolytic streptococci from 
normal and abnormal lymph nodes may be those which escaped elimination. Unless the 
organisms of doubtful pathogenicity are isolated more than once in serial blood cultures, 
they have little significance.  
 
PATHOLOGY: 
 
ACUTE INFECTION: 
Most episodes of acute pharyngotonsillitis are caused by viruses such as 
Adenovirus, coronavirus, enterovirus, rhinovirus, respiratory synctitial virus (RSV), 
Ebstein Barr Virus, Herpes Simplex Virus and Metapneumo virus. Next to viral 
infections, GABHS is being the most common cause of bacterial infection in the pharynx. 
Additional bacterial organisms can include other beta-hemolytic streptococci, Group C, 
Staphylococcal aureus, gram negative organisms, Mycoplasma pneumoniae, Neisseria 
gonorrhoea and Corynebacterium diphtheriae. 
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Oral candidiasis can occur in immunocompromised children who have been 
treated chronically with antibiotics or inhaled steroids. 
 
CHRONIC INFECTION: 
Occurs by multiple microbes, which include high incidence of beta-lactamase 
producing organisms such as; 
Aerobic: Streptococci, H.influenzae, 
Anaerobic: Peptostreptococcus, Provotella, Fuobacterium predominate etc. 
 
TONSILLAR CRYPTS:  
The accumulated desquamated epithelial cells, lymphocyte, bacteria and other 
debris cause cryptic tonsillitis. These cryptic plugs can calcify into tonsillar concretions 
or tonsilloliths. 
 
AIRWAY OBSTRUCTION: 
  Both the tonsil and adenoid hypertrophy are a major cause of upper respiratory 
tract obstruction in children.  
 
TONSILLAR NEOPLASM: 
Rapid enlargement of one tonsil is highly suggestive of a tonsillar malignancy, 
typically lymphoma in children. 
  
 
  
Acute Pharyngo-tonsillitis 
 
 
 
Tonsillitis with exudates 
30 
 
 
ACUTE PHARYNGOTONSILLITIS 
 
DEFINITION:  
Acute inflammation generally restricted to the tonsils, posterior pharynx, uvula, 
anterior cervical region. Acute pharyngotonsillitis is an infection restricted to the crypt 
and surface secretion. When referring to tonsillitis, the correct term is pharyngo-tonsillitis 
(PT) as the pharynx has lateral cords with the same type of tissue 
lymphatic ring.  
In previous studies on acute pharyngotonsillitis, it is found that the secretion in 
crypts and at the surface was infected in acute pharyngotonsillitis while no bacteria were 
detected in the parenchyma. Based on these results, researchers have proposed a new 
hypothesis stating that the infection is restricted to the crypt and surface secretions in 
acute pharyngotonsillitis.  
 
EPIDEMIOLOGY:  
In a survey involving 429 pediatricians in the United States, Upper respiratory 
tract infections and ear infections were the most common causes for a visit.   
Pharyngo-tonsillitis was the third most common problem, responsible for 17 % of the 
visits, according to the age of the child. 
 
PREVALENCE AND DISTRIBUTION: 
GAS most often affects children and young adults (5-15 years of age). Infection is 
most common during the winter and early spring. GAS is the cause of approximately   
15-30% of acute pharyngo-tonsillitis in children and 5-10% in adults7. 
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ETIOLOGY: 
VIRAL:  
Adenovirus, Rhinovirus, Coxsackie viruses A & B, influenza virus, Para influenza 
virus, Echo virus and Respiratory Syncytial virus and Epstein Barr virus. 
 
BACTERIAL:  
Usually caused by Group A Beta-Hemolytic streptococci. Less common 
pathogens include S.aureus, H.influenzae, M.catarrhalis, Diphtheriae, Gonococci, 
chlamydiae.  
Mycoplasma pneumoniae and Candida albicans have also been incriminated. 
Irritant fumes and smoke also cause irritation of the throat. 
 
MICROBIOLOGY: 
In a study, about 54% of the patients8, an initial throat swab did not grow any 
pathogenic organism. Positive swabs were mostly of GABHS or Staphylococcus aureus. 
Group A -haemolytic streptococcus (GABHS) is one of the major causes of tonsillitis. 
However, other aerobic and anaerobic organisms can be isolated from the surface and 
core of normal and inflamed tonsils. The exact role of these organisms is uncertain, and 
some are believed to be part of the normal oropharyngeal flora, as we saw earlier. 
Anaerobic bacteria predominate in the normal oral flora, outnumbering aerobic bacteria 
in a ratio of 10:1. 
 
 GABHS is the best known cause of pharyngotonsillits, 
 Occasionally, groups B, C and G beta-hemolytic streptococci are responsible, 
Streptococcus pneumoniae infections may be self-limited or it may spread to 
other sites. 
 Corynebacterium diphtheriae produces a lethal exotoxin that is absorbed 
from the site of infection and carried to other organs, such as the throat, 
palate, and larynx. 
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 Arcanobacterium hemolyticum infection affects the 15-18-year age group and 
accounts for 2.5- 10% of all cases of pharyngotonsillitis.  
 Neisseria gonorrhoeae infection is more common in homosexual males and 
may be associated with pharyngitis in adolescents. It can result in bacteremia 
and may persist after treatment.  
 Neisseria meningitidis can cause symptomatic or asymptomatic 
pharyngotonsillitis which can be a prodrome for septicemia or meningitis.  
 Staphylococcus aureus is often isolated from chronically inflamed tonsils and 
peritonsillar abscesses. The bacterium produces betalactamase which can 
interfere with the eradication of GABHS.  
 Nontypable H. Influenzae and H. parainfluenzae may be recovered from 
inflamed tonsils. These agents can cause invasive disease in infants and the 
elderly, as well as acute epiglottitis, otitis media, and sinusitis. High tissue 
concentrations of H. Influenzae, Staphlococcus aureus and GABHS correlate 
with clinical parameters of recurrent infection and hyperplasia of the tonsils.  
 In rare cases, pharyngotonsillits is caused by Francisella tularensis, 
Treponema pallidum, Mycobacterium spp, or Toxoplasma gondii.  
 The anaerobic species that have been implicated in pharyngotonsillitis are 
Actinomyces, Fusobacterium, and gram negative bacilli (e.g.pigmented 
Prevotella and Porphyromonas spp.and Bacteroides spp.). The role of 
anaerobes is supported by their predominance in tonsillar or retropharyngeal 
abscesses and Vincent's angina (Fusobacterium spp. and spirochetes). 
Elevated serum levels of antibodies to Prevotella intermedia and 
Fusobacterium nucleatum have been found in patients with recurrent non-
GABHS tonsillitis and peritonsillar cellulitus and abscess. 
 Mycoplasma pneumoniae and Mycoplasma hominis can also cause 
pharyngotonsillitis, usually as a manifestation of a generalized infection. The 
prevalence of Mycoplasma infection increases with age.  
 Chlamydiae pneumoniae infection often accompanies pneumonia or 
bronchitis. 
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PRECIPITATING FACTORS : 
In children, history of attacks is precipitated by intake of cold drinks (aerated 
drinks as well as juice), ice-creams, fried items and passive smoking. These factors could 
possibly be acting by  
 Altering the bacterial micro flora   and/or 
 Lowering host immunity by altering local factors in the throat. 
 
TRANSMISSION: 
Major source of the streptococcus pyogenes is the human upper respiratory tract 
ie. Throat, nasopharynx or nose of the patients and carriers. Nasopharynx and oropharynx 
are the main sites of colonization. Carrier rates of up to 20% have been observed.  
Aerosol secretions of the upper respiratory tract are the primary transmitting 
source of the causative agents. Transmission is either by direct contact or through 
contaminated fingers, dust or fomites. 
 Risk of contagion depends on the amount that was inoculated and on the 
virulence of the strain. Thus, individuals are more prone to become infected in the early 
stages of disease. Crowding is an important factor in the transmission of infection. 
Outbreaks of infection may occur in closed communities such as boarding schools or day 
care centers.  
The incubation period is from 1 to 4 days and most physicians allow children to 
go back to school 48 to 72 hours after the antimicrobial treatment is started. The rate of 
transmission of GAS in untreated patients is approximately 35% in close contacts, such 
as family members or schools. 
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GENERALISED CLINICAL FEATURES: 
Irrespective of the type of Pharyngotonsillitis, the following are the classical features 
 
Symptoms  
 Odynophagia,  
 sorethroat,  
 malaise, fever and chills,  
 dysphagia,  
 referred otalgia,  
 headache,  
 muscular aches and 
 enlarged lymph nodes. 
 
Signs 
 Dry tongue,  
 Erythematous enlarged tonsils,  
 Tonsillar/pharyngeal exudates,  
 Palatine petechiae,  
 Enlargement & tenderness of jugulo-digastric lymphnodes. 
 
VIRAL PHARYNGOTONSILLITIS: 
The predominance of viral infections is very high in children younger than 3 years 
of age, an age group where pharyngo-tonsilitis caused by GABHS is rare. The onset is 
gradual and there is less toxaemia.  An irritation of the pharynx / tonsils is frequently 
found with viral infections.  
Children with viral infections often have extra-pharyngeal signs and symptoms, as 
nasal secretions, conjunctivitis, cough, hoarseness, diarrhea, ulcerations or other clinical 
manifestations highly suggestive of viral infections.  
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It presents with grayish or yellowish white discrete areas of exudate on tonsils 
with pharyngeal erythema and tender cervical lymphadenopathy.  
The classical symptoms of viral infections namely, cough, rhinitis, conjunctivitis, 
and diarrhea, are usually absent in bacterial pharyngotonsilitis. (According to the clinical 
index developed by McIsaac and colleagues) 
 
BACTERIAL PHARYNGOTONSILLITIS : 
GABHS has been the most common cause of acute pharyngotonsillitis, its 
importance not only lies in the frequency but due to its serious sequelae ie, acute 
rheumatic fever and post streptococcal glomerulonephritis.  
The onset is sudden, acute, charachterised by odynophagia, high fever, headache 
and abdominal pain. 
Signs and symptoms of pharyngotonsillitis caused by GABHS can vary from mild 
pain in the throat and malaise (30% to 50% of cases) to high fever, nausea, vomiting and 
dehydration (10% of cases).  
The mucosa in the pharynx and tonsils is typically hyperemic, with occasional 
edema, exudate being present in 50% - 90% of the cases.  
Petechiae or doughnut lesions on the soft palate or posterior pharynx. Uvula is 
red, stippled and swollen.  
Cervical adenopathy is very common (30% - 60% of cases). When present in the 
classical form, the scarletiniform exanthema is very indicative of a bacterial infection, but 
is not frequent. GABHS pharyngotonsillitis tends to present with exudative pharyngitis.  
Younger children may not complain of sorethroat but often refuse to feed 
normally. 
 
COURSE OF ILLNESS: 
Viral pharyngotonsillitis is usually associated with nasal secretions and is 
generally self-limited (4-10 days), whereas bacterial illness, if left untreated, lasts longer. 
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DIAGNOSIS: 
difficult in interpreting data of samples and differentiating between the organisms that are 
colonized and those that are invaders. Several studies have documented that most 
physicians empirically start antimicrobial therapy for suspected acute pharyngitis and 
may not collect a swab for throat culture10. 
 
1. Complete Blood Count (CBC): Neutrophil count in the peripheral blood is 
elevated in streptococcal infections. 
2. An increase in antistreptolysin O (ASO) streptococcal antibody titer after 3-6 
weeks can provide retrospective evidence of GABHS infection. The usual test 
done is anti streptolysin O titration. ASO Titres > 200 are indicative of prior 
streptococcal infection. 
3. High CRP value is seen in streptococcal infections. In patients with streptococci 
group C or G an elevated CRP-value was significantly associated. 
4. Culture from the tonsils, tonsil crypts or pharynx  : was earlier considered as 
golden standard for the definite etiologic diagnosis of a Pharyngo tonsillitis  
(due to 95% specificity in GABHS identification) but now judged to be an 
imperfect gold standard for diagnosing streptococcal pharyngitis because of the 
following: 
a. False positive cultures can occur if the organisms are misidentified as GABHS. 
b. Children who are streptococcal carriers can also have positive cultures. 
c. False negative cultures are attributed to a variety of causes including inadequate 
throat swab specimens and patients surreptious use of antibiotics. 
5. Rapid Streptococcal antigen detecting test: Gives result within 10 minutes. The 
specificity is high. If rapid test is positive, indicates appropriate treatment. 
6. If rapid strep test is negative, confirmation with throat culture is considered 
mandatory on account of clinical suspicion of GABHS. 
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7. Viral cultures often unavailable. It is too expensive and too slow to be clinically 
useful. 
8. Viral Polymerase Chain Reaction (PCR): more rapid and may be useful but not 
always necessary. 
9. Monospot or Paul-Bunnel Test or Slide Agglutination test: helps confirm EBV 
infectious mononucleosis. 
10. A lateral soft tissue X ray film of the Head and Neck region will show up the 
hypertrophic tonsils and adenoids together with narrowing of naso and 
oropharynx. 
 
Short duration of symptoms, considerable pain on swallowing, an age of 3 to 14 
years, an elevated CRP value and four Centor criteria (fever, anterior cervical 
lymphadenopathy, tonsillar rubor and exudates, and lack of cough) are of significant 
value in diagnosing streptococcal pharyngotonsillitis.  
 
For tonsillar hypertrophy, the following scale is usually used in clinical practice. 
Size & Percentage of Obstruction:  
1. GRADE 0 : tonsil is in fossa 
2. GRADE 1 :  less than 25% obstruction 
3. GRADE 2 :  less than 50% obstruction 
4. GRADE 3 :  less than 75% obstruction 
5. GRADE 4:  more than 75% obstruction. 
 
In adults, the Centor criteria are most often used. The 4 criteria are: 
1. Tonsillar exudates; 
2. Tender anterior cervical adenopathy; 
3. Fever by history; 
4. Absence of cough. 
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Persons with three or four of these criteria may be treated empirically for GAS. Those 
with zero or one criterion do not need to be tested or treated. If two or three criteria are 
present, testing should be performed and patients treated only if the test is positive.  
 
The McIsaac modification of the Centor criteria is being used nowadays in children. 
Points for a patient are added based on the following scoring: 
1. history of fever or T>101°F (38oC) +1 
2. absence of cough +1 
3. tender anterior cervical adenopathy +1 
4. tonsillar swelling or exudates +1 
5. age <15 years +1 
6. age > or = 45 years -1 
 
Children with 0 points are unlikely to have GAS infection and do not need to be 
tested. Those with 1-3 points should be tested and treatment based on the test result. 
Those with 4-5 points have a high likelihood of having GAS infection and may be treated 
empirically or tested and treated if the test is positive. 
 
ASSESSMENT: 
The improvement in case of pharyngo-tonsillitis can also be assessed by the 
improvement in the symptoms such as difficulty in feeding in small children, mouth 
breathing, noisy respiration, loud snoring, frequent awakening or hypersomnolence, 
secondary eneuresis, night terrors or changes in behaviour pattern (Pavor Nocturnus). 
Regular monitoring of the improvement in the symptomatology proves to provide 
clue for clinical prognosis and assessment of management. 
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DIFFERENTIAL DIAGNOSIS:  
1. Narrowing and spasm of trachea and bronchi may also cause sensation of 
sorethroat with a constant desire to clear the throat. 
2. Primary HSV infections in young children often present as high fever and 
gingivostomatitis but pharyngitis may be present. 
3. 
Patients have dysphagia, sorethroat and papulovesicular lesions surrounded by 
erythema over the tongue, pharynx, anterior tonsillar pillars and soft 
palate.Pharynx appears congested with the presence of small yellowish white 
nodules. 
4. Diphtheria: Corynebacterium diphtheriae infection causes a bull neck and an 
early exudative pharyngotonsillitis characterized by the development of a 
grayish-green thick membrane that is difficult to dislodge, and when torn off, 
often leaves a bleeding surface. Associated moderate fever and toxaemia are 
present.  
5. Agranulocytosis: Blood count shows neutropenia. 
6. Pharyngoconjuctival fever: patients have fever, conjunctivitis, pharyngitis and 
cervical lymphadenitis due to infection with adenovirus type III. 
7. Infectious mononucleosis: Charachterised by lymphadenopathy, mobiliform 
rash, hepatosplenomegaly, generalized fatigue and sometimes aseptic 
-
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8. Gonococcal pharyngeal infections are usually asymptomatic though some 
exhibit pharyngeal ulcers or exudates. It can cause acute pharyngitis with fever 
and cervical lymphadenitis. 
9. Mycoplasma pneumoniae infection occurs only in early adolescence.  
 
COMPLICATIONS: 
Many of the pharyyngotonsillitis complications include the obstructive, 
infectious, toxin-mediated or immunomediated. 
 
OBSTRUCTIVE: 
Patients with tonsillar hyperplasia can have breathing difficulties, in general when 
the acute tonsillar inflammation leads to edema. In certain infections, as caused by the 
Epstein Barr virus, the degree of edema can be so severe that tonsils that are generally 
non obstructive can interfere with breathing. This is typically manifested in sleep-
disordered breathing including Obstructive sleep apnea, Hyperpnoea and upper airway 
resistance syndrome. 
 
INFECTIOUS:  
This includes both suppurative and non-suppurative. Streptococcus pyogenes 
infections lead to two important non-suppurative sequelae. 
 Acute glomerulo-nephritis (AGN): the acute nephritic syndrome can develop 1 
to 2 weeks after an acute streptococcal infection and complicates approximately 
5% of cases of GABHS pharyngitis in children. The early administration of 
antibiotics does not prevent this sequela. The most frequent form of AGN is the 
IgA-mediated nephropathy, associated with chronic tonsillitis. 
 Acute Rheumatic fever (ARF): it is the most serious infectious complication of 
the acute streptococcal Pharyngotonsillitis. ARF happens in < 3% of untreated 
cases of GAS during an epidemic and in < 0.5% of sporadic cases.  It ensues 1 to 
3 weeks after the acute infection so that the organism may not be detectable when 
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sequelae set in. this clinical entity presents with triad of arthritis, carditis and 
chorea. It can also lead to a heart valve disease ie, mitral stenosis.  
 
From the throat, streptococci may invade to the surrounding tissues, leading to 
suppurative complications such as  
 Otitis media 
 Sinusitis. 
 Peritonsillar abscess is the most common infectious complication resulting from 
an extensive acute exudative tonsillitis.  
 Retropharyngeal or parapharyngeal abscesses. 
 Mastoiditis 
 Quincy 
  
 Suppurative cervical adenitis. 
 Supraglotitis 
 Cellulitis 
 Fasciitis 
 Peritonitis 
 Arthritis 
 Osteomyelitis 
 Thyroditis 
 Meningitis  
 Bacteremia 
 The infection may spread down the tracheobronchial tree causing 
tracheobronchitis and pneumonia. 
 
Therapy with antibiotics can prevent the above suppurative complications and rheumatic 
fever among non-suppurative complications. However, a final conclusion has not been 
reached yet about post-streptococcal acute glomerulonephritis being prevented by 
antibiotic therapy. 
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TOXIN-MEDIATED:  
 Scarlet fever is a classical, toxin-mediated form of infection by GABHS 
 Another toxin mediated disease associated with GABHS is the necrotizing 
fasciitis or Toxic shock syndrome. 
 Recently a new syndrome called PANDAS (Pediatric Autoimmune 
Neuropsychiatric Disorder Associated with Group A Streptococci) has been 
described. The syndrome involves obsessive-compulsive disorder or tic 
disorder with other neurologic abnormalities of abrupt onset in association 
with GABHS infections. A clear cut relationship between the syndrome and 
GABHS infection is yet to be published. 
 
TONSILLECTOMY: 
The most followed curative treatment nowadays is surgical removal of tonsils. 
Adenoidectomy & Tonsillectomy are currently one among the top 10 pediatric surgeries.  
In the first century AD, Celsus described tonsillectomy performed with sharp 
tools and followed by rinses with vinegar and other medicinals. Since that time, 
physicians have been documenting surgical management of tonsillitis. 
 
INDICATIONS FOR TONSILLECTOMY: 
The current clinical indications for tonsillectomy are:  
(As recommended by the AAO-HNS in 2000)  
 An important indication is recurrent or chronic pharyngo-tonsillitis.  
 3 or more infections per year despite adequate medical therapy. 
 Hypertrophy causing dental malocclusion or adversely affecting oro-facial 
growth documented by orthodontist 
 
43 
 Hypertrophy causing upper airway obstruction, severe dysphagia, sleep 
disorders (obstructive sleep apnea) 
 Unilateral tonsil hypertrophy presumed to be neoplastic. 
 cardiopulmonary complications 
 Peritonsillar abscess unresponsive to medical management and drainage 
documented by surgeon (except when surgery is performed during acute 
stage) 
 Persistent foul taste or breath due to chronic tonsillitis not responsive to 
medical therapy;  
 Previous peritonsillar abscess may be a relative indication.  
 Significant missed time from school or work should prompt for 
tonsillectomy.  
 
DEMERITS OF TONSILLECTOMY: 
 Tonsillectomy and adenoidectomy results in a major loss of pharyngeal 
lymphoid tissue. 
 Dehydration from odynophagia is common in the first post operative week. 
 
 Immunization against poliomyelitis in post-tonsillectomy patients has a higher 
incidence of bulbar poliomyelitis. 
 Swelling of the tongue and soft palate may lead to acute airway obstruction in 
the first few hours after surgery. Children with underlying hypotonia or 
craniofacial anomalies are at greater risk of suffering this complication 
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 Bleeding may occur in the immediate post-operative period or be delayed 
after separation of eschar. Postoperative hemorrhage is considered the most 
significant risk. 
 Rare complications include velopharyngeal insufficiency, nasopharyngeal or 
oropharyngeal stenosis  
  Psychological problems. 
 Tonsillectomy has not shown to offer clinical benefit over conservative 
treatment in children with mild symptoms. Furthermore, tonsillectomy does 
not prevent recurrence of pharyngeal infections.  
 No significant difference exists between the type and number of pathogens in 
patients undergoing adenotonsillectomy for recurrent infection or 
obstruction24&25.  
 
CARRIERS: 
organism, even after an appropriate antimicrobial therapy. Carriers are recognized as 
individuals that have a positive culture for this organism, although there is a very low risk 
that they will transmit GABHS or even develop sequelae. The rate of carriers reported in 
the literature varies from 3 to 40% depending upon the population being assessed. 
 
TREATMENT: 
Most untreated episodes of Streptococcal pharyngo-tonsillitis resolve 
uneventfully in a few days, but early antibiotic therapy hastens clinical recovery by 12 to 
24 hours. The treatment should be aimed at relieving symptoms of the acute disease 
(antipyretics, analgesics), eliminate transmissibility; prevent both suppurative and non-
suppurative sequelae. When selecting an antimicrobial for treatment of group A 
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streptococcal pharyngo-tonsillitis, important issues to consider include efficacy, safety, 
antimicrobial spectrum (narrow vs. broad), dosing schedule, associated compliance with 
therapy (i.e., adherence) and cost. These factors influence the cost-effectiveness of 
antimicrobial therapy. 
 
RECURRENT EPISODES OF PHARYNGOTONSILLITIS: 
The criteria is  
 7 or more throat infections treated with antibiotics in the preceding year 
 5 or more throat infections treated in each of the preceding two years 
 3 or more throat infections treated with antibiotics in each of the preceding 
three years. 
 
Inorder to control the recurrency, following strategies are to be followed:    
 Smoky and dusty atmosphere should be avoided. 
 Dampness in the environment and overcrowding are to be better avoided. 
  improved by good nutritious diet. 
 A detailed history should be obtained and physical examination conducted for 
proper evaluation.  
 Paranasal sinuses and ears should be examined for the foci of infection and if 
present, should be adequately treated.  
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DRUG REVIEW  
(PROPERTIES OF TRIAL DRUG INGREDIENTS) 
¦¸¡òÐÁøÄ¢ 
Botanical Name: Coriandrum sativum, Linn 
Classical /Vernacular Names: ¯Õû«Ã¢º¢, ¾É¢Â¡ 
Natural Order: Apiaceae 
Í¨Å:¸¡÷ôÒ 
¾ý¨Á: º£¾ ¦ÅôÀõ 
À¢Ã¢×: ¸¡÷ôÒ 
¦ºö¨¸: ¦ÅôÀÓñ¼¡ì¸¢, «¸ðÎÅ¡öÅ¸üÈ¢, Àº¢òò£àñÊ, º¢Ú¿£÷¦ÀÕì¸¢ 
Ì½õ: 
¦¸¡òÐÁøÄ¢ ¦ÅôÀõ Ìª¢÷¸¡öîºø À¢ò¾Áó¾ï 
º÷ò¾¢Å¢ì¸ø ¾¡¸¦Á¡Î ¾¡Ð¿ð¼õ-¸ò¾¢¦ÂØõ 
Å¡¾ Å¢¸¡÷Á¼÷ Åý¸÷ò¾ À¢Å¢Ã½õ 
â¾Äò¾¢ø Ä¡¾¸üÚõ §À¡üÚõ. 
   - «¸ò¾¢Â÷ Ì½Å¡¸¼õ. 
Botanical Description: 
 Fruits yellowish brown, globose, 4-5 mm in diameter, ribbed, separating into two 
halves. Seeds compressed. 
Parts Used:  Whole plant, fruit 
Pharmacognosy: 
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 Fruits is subglobose, glabrous, schizocarp, about 5 mm in diameter, splitting into 
two hemispherical mericarps. Each mericarp has 5 wavy, rather inconpicious, primary 
ridges alternating with 4 more prominent secondary ridges. 
Physical Constituents: 
 Total ash: not more than 6% 
 Acid insoluble ash: not more than 1.5% 
 Alcohol soluble extract: not less than 10% 
 Water soluble extract: not less than 19% 
 Volatile oil: not less than 0.3%. 
Chemical Constituents: 
 D-mannitol, flavonoid glycosides, coriandriononediol, quercetin-3-0-caffeyl-
glucoside, kaempferol 3-glucoside,, limonene, borneol, caryophyllene, thymol, geranyl 
acetate. 
Pharmacological Activity: 
Anti-microbial, spasmolytic. 
Extract of seed shows fungitoxic effect against Helminthosporium oryzae. 
Coriander sativum which was commonly used flavouring agent in food. The essential oil 
from coriander was found to have antibacterial activity (Silva etal, 2011). Also safety 
assessment of coriander showed no toxic effects (Burdock etal, 2009). 
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ºýÉÄÅí¸ôÀð¨¼ 
Botanical Name: Cinnamomum verum, Presl 
Classical /Vernacular Names: ¸ÕÅ¡ôÀð¨¼ 
Natural Order: Lauraceae 
Í¨Å: ¸¡ÃÓõ ­É¢ôÒ¨¼ÂÐ 
¾ý¨Á: ¾ðÀõ 
À¢Ã¢×: ­É¢ôÒ 
¦ºö¨¸: ¦ÅôÀÓñ¼¡ì¸¢, «¸ðÎÅ¡öÅ¸üÈ¢, ¸¡Áõ¦ÀÕì¸¢ 
Ì½õ: 
  
â¾¸¢Ã ¸ïº¢Äó¾¢ô âîº¢Å¢¼  -º¡¾¢Å¢¼õ 
¬ðÎÁ¢¨Ãô §À¡ÊÕÁø ¬¸¢Â§¿¡öì Üð¼ÁÈ 
µðÎÁ¢Ä Åí¸ ÐÃ¢. 
- «¸ò¾¢Â÷ Ì½Å¡¸¼õ. 
Botanical Description: 
 An evergreen tree, 8-16m high, with reddish brown bark having numerous small 
warts. 
Parts Used:  Bark 
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Pharmacognosy: 
 Bark pieces are about 0.5 mm thick, brittle; outer surface dull yellowish-brown, 
marked with pale wavy longitudinal lines with occasional small scars or holes; inner 
surface darker in colour, striated with longitudinally elongated reticulation;  
 Odour fragnant; taste sweet, aromatic. 
Physical Constituents: 
 Total ash: not more than 3% 
 Acid insoluble ash: not more than 2% 
 Alcohol soluble extract: not less than 2% 
 Water soluble extract: not less than 3% 
 Volatile oil: not less than 1%. 
Chemical Constituents: 
 Cinnamaldehyde, eugenol, benzaldehyde, cymene, cumic aldehyde, linalool, 
benzyl acetate, cinnmic aldehyde, eugenyl acetate, cinnamyl acetate, benzyl benzoate, 
cinncassiol Cl glucoside, cinncassiol C2 and  cinncassiol C3, cinncassiol D1, its 
glucoside. 
Pharmacological Activity: 
Anti-microbial,  Antiallergic,  Anti-complement,  Anti-Fungal,  Anti-oxidant, 
Antinociceptive 
­ÄÅí¸õ  
Botanical Name: Syzygium aromatica (Linn) Merrill & Perry 
Synonyms:  
Eugenia caryophyllata Thunb. 
Eugenia aromatica Kuntze. 
Caryophyllus aromaticus Linn. 
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Classical/Vernacular Names:  
«ïÍ¸õ, ¯ü¸¼õ, ¸ÕÅ¡öì ¸¢Ã¡õÒ, §º¡ºõ, ¾¢Ãª¢, ÅÃ¡í¸õ. 
Natural Order: Myrtaceae 
Í¨Å: ¸¡ÃÓõ, Å¢ÚÅ¢ÚôÒÓûªÐ; 
¾ý¨Á: ¦ÅôÀõ 
À¢Ã¢×: ¸¡÷ôÒ 
¦ºö¨¸:  
­º¢Å¸üÈ¢, «¸ðÎÅ¡öÅ¸üÈ¢, Àº¢ò¾£òàñÊ 
Ì½õ: 
À¢ò¾ÁÂì¸õ §À¾¢¦Â¡Î Å¡ó¾¢Ôõ§À¡õ 
Íò¾Å¢Ãò ¾ì¸ÎôÒó§¾¡ýÚ§Á¡- ¦Áò¾ 
­ÄÅí¸í ¦¸¡ñ¼ÅÕì §¸ü Í¸Á¡Ìõ 
 
 
º¢ì¸øÅ¢¼¡î º÷Å¡ º¢ÂôÀ¢½¢Ô-Áì¸¢ìÌð 
¼í¸ô â§Å¡Î ¾Ã¢À¼Õó §¾¡ýÈ¢Â¢ø 
 
   - «¸ò¾¢Â÷ Ì½Å¡¸¼õ. 
 ¾½Ä¢ø Å¾ì¸¢, Å¡Â¢Ä¢ðÎî Í¨Åì¸ ¦¾¡ñ¨¼ô Òñ ¬Úõ. 
 ­ÄÅí¸ò ¨¾Äõ: «Ø¸Ä¸üÈ¢, ¯½÷îº¢ §À¡ì¸¢ ¦ºö¨¸Ô¨¼ÂÐ. 
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Botanical Description: 
Flower buds: Greenish to pink, aromatic, clustered at the ends of branches 
Parts Used: Flower buds, oil 
Pharmacognosy: 
 Flower bud is 10-17.5mm long; dark brown/dusty red colour, consisting of a sub-
cylindrical, slightly flattened, four sided hypanthium, readily exuding oil when pressed. 
Odour is strongly aromatic; taste pungent, aromatic followed by slight tingling of the 
tongue. Clusters of calcium oxalate crystals are present in stalk. 
Physical constituents: 
 Foreign matter: not more than 2% 
 Total ash: not more than 7% 
 Acid insoluble ash: not more than 1% 
 Alcohol soluble extract: not less than 3% 
 Water soluble extract: not less than 9% 
 Volatile oil: not less than 15% 
Chemical constituents: 
Isobiflorin, Biflorin( Flower bud),  
Eugenol, Acetyl eugenol, Eugeniin, Eugenone , Eugenol acetate, Eugenine 
Eugenitone, Isoeugenitol (clove oil) 
Caryophyllene, Epoxydihydrocaryophyllene, Ellagitannin- Syzyginins A, Syzyginins-
B (leaves). 
Pharmacological activity: 
Anti-fungal, antiviral, antibacterial, cholagogue, antimicrobial, anticarcinogenic, 
radical scavenging activity, histamine release inhibitory activity. 
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Syzygium aromaticum widely used spice in food. Eugenol was found as major 
component in clove 
Antibacterial Activity of Eugenol: A crude MeOH extract of Syzygium aromaticum 
(clove) exhibited preferential growth-inhibitory activity against Gram-negative anaerobic 
periodontal oral pathogens, including Porphyromonas gingivalis and Prevotella 
intermedia.  Eugenol was found to be potent bactericidal component in essential oil 
extracts, against fastidious and facultative anaerobic oral bacteria. Eugenol was also 
found that a synergistic antimicrobial effect with erythromycin. 
Anti-Viral Effects: Eugenol found  in clove and bay oils [Clove oil is the greatest source 
of eugenol (70.9% eugenol)]  have virucidal effects as it is reported to inhibit herpes virus 
replication in vitro. 
Anti-Fungal Effects: Eugenol displayed potent activity against C. albicans biofilms in 
vitro with low cytotoxicity and therefore has potential therapeutic  
implication for candidal infections. 
Anaesthetic action of Eugenol: Molecular mechanism for local anesthetic action of 
eugenol in the trigeminal system is identified. 
Antipyretic action of eugenol:The analgesic agent eugenol reduced fever when given 
intravenously in small doses. Eugenol was more effective in reducing fever than 
acetaminophen.       
 Antioxidant action of eugenol: Free radical scavenging activity, metal chelation and 
antioxidant power as shown by the higher DPPH radical scavengine activity of Cloves 
followed by cardamom ingredients of the trial drug Malli chooranam. Eugenol and its 
derivatives are responsible for potent anti-oxidant action. 
 Clove exerted immunomodulatory/anti-inflammatory effects by inhibiting LPS 
action. A possible mechanism of action probably involved the suppression of the nuclear 
factor-
(Bachiega TH etal, 2012). 
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Substitutes and adulterants:  
Mother of cloves, clove stems, exhausted cloves, withered cloves, clove dust 
containing broken stamens, farinaceous products, cereal starches, ground fruit, unripe 
fruits of Cinnamomum verum J. S. Presl. 
The biological activity of Eugenia caryophyllata has been  
investigated on several microorganisms and parasites, including pathogenic bacteria, 
Herpes simplex and hepatitis C viruses.  In addition to its antimicrobial, antioxidant, 
antifungal and antiviral activity, clove essential oil possesses antiinflammatory, cytotoxic, 
insect repellent and anaesthetic properties.  
²Äõ:  
Botanical Name: Elettaria cardamomum Linn 
Classical /Vernacular Names: ¬­ïº¢, §¸¡Ãí¸õ, ÐÊ 
Natural Order: Zingiberaceae 
Í¨Å: ¸¡÷ôÒ 
¾ý¨Á: ¦ÅôÀõ 
À¢Ã¢×: ¸¡÷ôÒ 
¦ºö¨¸: ¦ÅôÀÓñ¼¡ì¸¢, «¸ðÎÅ¡öÅ¸üÈ¢, Àº¢òò£àñÊ 
Ì½õ: 
 
  §¾¡ýÚõ §¿¡Â¾¢ º¡ÃõÀý §Á¸ò¾¡ø 
¯ñ¨¼ §À¡¦ÄØõ ¸ðÊ ¸¢Ã¢îºÃõ 
  ¯Æ¨Ä  
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Àñ¨¼ ¦Åì¨¸ Å¢¾¡¸ §¿¡ö ¸¡ºÓõ 
  À¡Øï §º¡ÁôÀ¢½¢ Å¢óÐ ¿ð¼Óõ 
«ñ¨¼ Â£¨ªÅý À¢ò¾õ ­¨Å¦¸øÄ¡õ 
  ¬Ä Á¡í¸Áú ²Ä-  
- §¾¨ÃÂ÷ Ì½Å¡¸¼õ. 
     ¦¾¡ñ¨¼, ¾¡û, Å¡ö, ¸£ú Å¡ö ­¨Å¸ª¢ø ¯ñ¼¡Ìõ §¿¡ö¸¨ªÔõ, 
­ÕÁø, ¦¿ïº¢ý §¸¡¨Æ ¸ðÎ, ¸Æ¢îºø ­Åü¨ÈÔõ §À¡ìÌõ. «Æ¨Ä ¬üÚõ. 
 
 
ºÄãÈø Å¡Â¢É¢ôÒ ¾¡¸ï ºÄ§À¾¢ 
§Å÷ìÌó ¾¨Ä §¿¡ö Á¢Ìåð¨º ¨ÂÂÁ¢¨Å 
 
    - «¸ò¾¢Â÷ Ì½Å¡¸¼õ. 
 Å¡ö ¿£åÈø, ¿£÷ §Åð¨¸, §Å÷¨ÅÔ¼ý ÜÊÂ ¾¨ÄÅÄ¢, Á¢Ìó¾ ÅÈðº¢, 
¸Àõ ­¨Å¸¨ª §À¡ìÌõ ­ÂøÒ¨¼ÂÐ. 
 
Botanical Description: 
Fruits trilocular, subglobose or fusiform to ovoid capsule, brownish black, angled, 
rugose, covered with a thin mucilaginous membrane. 
Parts Used:  Fruits, Seeds 
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Pharmacognosy: 
Fruit: 1-2 cm long, ovoid, oblong, more or less three sided with rounded angles; 
greenish to pale or yellowish in colour, surface with longitudinal striations; fruit 
trilocular; each fruit containing about 10-15 seeds in a row of doubles. Seeds are dark 
brown to black, transversely wrinkled; odour strongly aromatic, taste charachteristic. 
Perisperm is of thin walled cells packed with rounded polyhedral starch grains 
and containing prismatic crystals of calcium oxalate. 
Physical Constituents: 
 Total ash: not more than 6% 
 Acid insoluble ash: not more than 4% 
 Alcohol soluble extract: not less than 2% 
 Water soluble extract: not less than 10% 
 Volatile oil: not less than 4%. 
 
Chemical Constituents: 
Alpha-Pinene, Sabinene, Myrecene, Limonene, Cineole, Cymene, Methyl 
Heptenone, Linalool, Linalyl acetate, Alpha and Beta Terpineol, Alpha- Terpinyl acetate, 
Borneol, Neryl acetate, Geraniol, Nerol, Neolidol, Heptacosane, Camphene, Terpinene, 
Alpha-Humulene. 
Pharmacological Activity: 
Anti-microbial, Analgesic, Anti-inflammatory, Anti-Fungal, Anti-Spasmodic, 
hepatoprotective. 
Cardamom seeds are widely used for flavouring purposes in food and as 
carminative. . A comparative study of the anti-inflammatory activity of the oil extracted 
from commercial Elettaria cardamomum seeds, in doses of 175 and 280 microliters/kg 
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and indomethacin in a dose of 30 mg/kg against acute carrageenan-induced planter 
oedema in male albino rats was performed, which proved to be marked. Moreover, 
investigation of the analgesic activity using p-benzoquinone as a chemical stimulus 
proved that a dose of 233 microliters/kg of the oil produced 50% protection against the 
writhing (stretching syndrome) induced by intraperitoneal administration of a 0.02% 
solution of p-benzoquinone in mice (al-Zuhair H etal, 2007) 
Substitutes and adulterants: 
 Amomum subulatum Roxb. as substitute 
Other common adulterants are:  
 E. cardamomum var. major Thw, 
 Amomum kepulaga Sprague and burkill 
 Amomum korarima Periera 
 Amomum aromaticum Roxb. 
 Amomum xanthioides Wallich 
 
¸Õïº£Ã¸õ 
Botanical Name: Nigella sativa.Linn 
Classical /Vernacular Names: «Ã½õ, ¯ÀÌïº¢¨¸ 
Natural Order: Ranunculaceae  
Í¨Å: ¨¸ôÒ  
¾ý¨Á: ¦ÅôÀõ 
À¢Ã¢×: ¸¡÷ôÒ 
¦ºö¨¸: ¦ÅôÀÓñ¼¡ì¸¢, «¸ðÎÅ¡öÅ¸üÈ¢, Àº¢òò£àñÊ, º¢Ú¿£÷¦ÀÕì¸¢, 
ÕÐ×ñ¼¡ì¸¢, À¡ü¦ÀÕì¸¢, ÒØì¦¸¡øÄ¢, ÅÈðº¢Â¸üÈ¢ 
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Ì½õ: 
 ¸Õïº£ Ã¸ò¾¡ý ¸ÃôÀ¦É¡Î ÒñÏõ 
ÅÕïº¢Ã¡öô À£¿ºÓ Á¡üÚõ-«Õó¾¢É¡ø 
¸¡öîºø ¾¨ÄÅÄ¢Ôí ¸ñÅÄ¢Ôõ §À¡ÓÄ¸¢ø 
Å¡öîº ÁÕó¦¾É§Å ¨Å. 
Botanical Description: 
 Seeds trigonous, black, rugulose-tubercular. 
Parts Used: seed, seed oil 
Pharmacognosy: 
 Seeds are small dicotyledonous, trigonous, angular, rugulose-tubercular, black 
externally and white inside, odour slightly aromatic; taste bitter. 
Physical Constituents: 
 Total ash: not more than 6% 
 Acid insoluble ash: not more than o.2% 
 Alcohol soluble extract: not less than 20% 
 Water soluble extract: not less than 15% 
 Volatile oil: not less than 0.42%. 
 
Chemical Constituents: 
 esters of dehydrostearic and linoleic acid, aliphatic alcohol, carvone, d-limonene, 
cymene, nigellone, alkaloids, stearoids, nigellidine-indazole, alkaloid thymoquinone. 
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Pharmacological Activity: 
 Anti-microbial, Analgesic, Anti-inflammatory, Anti-Fungal, Anti-Spasmodic, 
hepatoprotective, Antipyretic, bronchodilator, galactogogue. 
The pharmacological actions of the crude extracts of the seeds (and some of its active 
constituents, e.g. volatile oil and thymoquinone) that have been reported include 
protection against nephrotoxicity and hepatotoxicity induced by either disease or 
chemicals. The seeds/oil have antiinflammatory, analgesic, antipyretic, antimicrobial and 
antineoplastic activity. The seeds are characterized by a very low degree of toxicity. 
Administration of either the seed extract or its oil has been shown not to induce 
significant adverse effects on liver or kidney functions (Ali BH etal, 2003). 
Thymoquinone, as one of the major components of nigella sativa had potent analgesic 
and anti-inflammatory property (Hajhashemi V etal, 2004). 
 
Botanical Name: Vitis vinifera Linn 
Classical /Vernacular Names: «Ã¡Å¡Ãõ, ¦¸¡ÊÓó¾¢Ã¢¨¸, ÁÐÃºõ, §¸¡ò¾¢Ã¢¨¸, 
¾¢Ã¡ì¸õ, À§Ä¡ò¾¨Á 
Natural Order: Vitaceae  
Í¨Å: ­É¢ôÒ 
¾ý¨Á: ¾ðÀõ 
À¢Ã¢×: : ­É¢ôÒ 
Botanical Description: 
 Seeds trigonous, black, rugulose-tubercular. 
Parts Used: Ripe fruit (dried), leaf, stem, flower 
 
59 
Pharmacognosy: 
 Mature dried fruit, a berry, is sticky and pulpy, dark brown to black in colour, 
oblong or oval, sometimes spherical. Odour sweetish and pleasant; taste sweet. 
Physical Constituents: 
 Total ash: not more than 3% 
 Acid insoluble ash: not more than 0.2% 
 Alcohol soluble extract: not less than 25% 
 Water soluble extract: not less than 70% 
Chemical Constituents: 
 3-monoglucosides of delphinidin, cyaniding, petunidin, peonidin, malvidin, acetyl 
and coumaryl glycosides, malic acid, tannic acid  
Pharmacological Activity: 
 Antifungal, antiulcer, hepatoprotective, antioxidant, antibacterial, antiherpetic, 
cardioprotective, antimutagenic. 
Vitis vinifera, known as the grapevine, is native to southern Europe and Western 
Asia. Grape seed and skin contain several active components including flavonoids, 
polyphenols, anthocyanins, proanthocyanidins, procyanidines, and the stilbene derivative 
resveratrol. Grape seed extract in particular has been reported to possess a broad 
spectrum of pharmacological and therapeutic effects such as antioxidative, anti-
inflammatory, and antimicrobial activities, as well as having cardioprotective, 
hepatoprotective, and neuroprotective effects (Nassiri-As M etal, 2009). 
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«¾¢ÁÐÃõ 
Botanical Name: Glycyrrhiza glabra Linn 
Classical /Vernacular Names: «Ã¡Å¡Ãõ, ¦¸¡ÊÓó¾¢Ã¢¨¸, ÁÐÃºõ, §¸¡ò¾¢Ã¢¨¸, 
¾¢Ã¡ì¸õ, À§Ä¡ò¾¨Á 
Natural Order: Fabaceae  
Í¨Å: ­É¢ôÒ 
¾ý¨Á: ¾ðÀõ 
À¢Ã¢×: : ­É¢ôÒ 
Botanical Description: 
 Hardy herb or undershrub attaining a height upto 2 m. 
Parts Used: Root 
Pharmacognosy: 
 Root is yellowish brown, longitudinally wringled externally:odour is faint and 
characteristic: taste sweetish. 
Chemical Constituents: 
 Glycyrrhizine, prenylated biaurone, licoargone: 
7- acetoxy-2- methyl-isoflavone, glyzaglabrin, quercetin, kaempferol, astragalin, 
liquiritigenin and isoliquiritigenin. 
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Pharmacological Activity: 
 Anti-microbial, antiviral, hypotensive, hepatoprotective, anti-exudative, 
spasmolytic, antidiuretic, antiulcer, antimutagenic, antipyretic, antioxidant, anti-
inflammatory, expectorant. 
Glycyrrhizin and liquorice extract of glycyrhhiza glabra showed anti-inflammatory action 
(Rackova L etal, 2007). 
º£Ã¸õ 
Botanical Name: Cuminum cyminum Linn 
Classical /Vernacular Names: «¨º, º£Ã¢, ¯ÀÌõÀ£ºõ, ¿üº£Ã¢, Ðò¾º¡õÀÄõ, 
À¢Ãò¾¢-Å¢¸¡, À¢ò¾¿¡º¢É¢, §À¡ºÉÌ§¼¡Ã¢, §Áò¾¢Âõ 
Natural Order: Umbelliferae 
Í¨Å: ¸¡÷ôÒ, ­É¢ôÒ 
¾ý¨Á: ¾ðÀõ 
À¢Ã¢×: ­É¢ôÒ  
¦ºö¨¸: ¦ÅôÀÓñ¼¡ì¸¢, «¸ðÎÅ¡öÅ¸üÈ¢, Àº¢òò£àñÊ, ÐÅ÷ôÀ¢ 
Ì½õ: 
À¢ò¾¦ÁÛ Áó¾¢Ã¢¨Âô À¢ýÉô ÀÎò¾¢ÂÅý 
ºòÐÕ¨Å ÔóÐÈóÐ º¡¾¢òÐ-Áò¾¦ÉÛõ 
Ã¡º¨ÉÔ Á£¦ÅýÚ ¿ñ¨Àô ÀÄôÀÎò¾¢ 
§À¡ºÉÌ ¼¡Ã¢¦ºÔõ §À¡÷. 
- §¾Ãý ¦ÅñÀ¡ 
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Botanical Description: 
 The fruit is a lateral fusiform or ovoid achene 4 5 mm long, containing  a single 
seed. 
Parts Used:  Fruit or seed 
Chemical Constituents: 
 Thymene, carvone, cuminol or cumic aldehyde, cymene cymol, terpene, carvone, 
- -terpinene, linalool,  p- - -
pinene, 1,8-cineole, o- and p- - -terpinene, safranal and linalool. 
Pharmacological Activity: 
Anti-microbial,  antioxidant, antidiabetic, immunomodulator, diuretic. 
Cuminum cyminum, which was used daily in food had antimicrobial action 
against fungi or bacteria (Zaman U etal, 2008). 
 
Botanical Name: Carum bulbocastum Koch 
Classical /Vernacular Names: À¢ªôÒº£Ã¸õ, º£¨Áîº£Ã¸õ 
Natural Order: Umbelliferae 
Í¨Å: ¸¡÷ôÒ, ­É¢ôÒ 
¾ý¨Á: ¾ðÀõ 
À¢Ã¢×: ­É¢ôÒ  
¦ºö¨¸: «¸ðÎÅ¡öÅ¸üÈ¢, º¢Ú¿£÷¦ÀÕì¸¢, ÕÐ×ñ¼¡ì¸¢ 
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Ì½õ: 
¯¼Öì ¸Æ¸¡õ ¯¨ÈôÀ¢ò¾õ ²Ìõ 
«¼ÖÚ Å¡¾õ «¾Á¡õ-¸Ê§º÷ 
¾ªÔ¿¨¸ì §¸¡ðÎÓ¨Äò ¨¾Â§Ä! ¿¡Ùõ 
À¢ª×¿Úï º£Ã¸ò¨¾ô §Àñ. 
Botanical Description: 
 The fruit is a lateral fusiform or ovoid achene 4 5 mm long, containing  a single 
seed. 
Parts Used:  Fruit or seed 
Chemical Constituents: 
 Thymene, carvone, cuminol or cumic aldehyde, cymene cymol, terpene, carvone, 
-pinene, -terpinene, linalool,  p- - -
pinene, 1,8-cineole, o- and p- - -terpinene, safranal and linalool. 
Pharmacological Activity: 
Anti-microbial,  antioxidant, antidiabetic, immunomodulator, diuretic. 
A number of EO components has been identified as effective antibacterials, e.g. 
carvacrol, thymol, eugenol, perillaldehyde, cinnamaldehyde and cinnamic acid (Burt S, 
2004). 
ÀÈí¸¢îºì¨¸ 
Botanical Name: Smilax china.Linn 
Classical /Vernacular Names:   
Natural Order: Liliaceae 
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Í¨Å: ­É¢ôÒ 
¾ý¨Á: ¾ðÀõ 
À¢Ã¢×: ­É¢ôÒ  
¦ºö¨¸:¯¼ø§¾üÈ¢, §Á¸ôÀ¢½¢Å¢Ä¸ì¸¢, ¸¡Áõ¦ÀÕì¸¢, àö¨ÁÂ¡ì¸¢ 
Ì½õ: 
¾¡¸õ ÀÄÅ¡¾ó ¾¡Ð¿ð¼õ ÒñÀ¢ª¨Å 
§Á¸í ¸Ê¸¢Ãó¾¢ Å£úãÄó-§¾¸Ó¼ý 
Ìð¨¼ À¸ó¾§Áü ¦¸¡ûÅÁÉõ §À¡õÀÈí¸¢ô 
Àð¨¼Â¢¨É ÔîºÃ¢òÐô À¡÷.    
  - §¾¨ÃÂ÷ Ì½Å¡¸¼õ. 
Botanical Description: 
 Rhizome blackish externally, pale coloured or whitish internally,  bitter, acrid. 
Parts Used:  Rhizome 
Chemical Constituents: 
  Kaemperol-7-O-beta-D-glucopyranoside , engeletin , isoengeletin , kaempferol , 
dihydrokaempferol , dihydrokaempferol-5-O-P-D-glucopyranoside , rutin , kaempferol- 
5-O-beta-D-glucopyranoside , 3, 5, 4'-trihydroxystibene , vanillic acid , 3, 5-dimethoxy4-
O-beta-D-glu-copyranosylcinnamic acid , beta-sitosterol , and beta-daucosterol. 
Pharmacological Activity: 
Anodyne,  anti-inflammatory, digestive, laxative, depurative, aphrodisiac, 
diuretic, febrifuge and tonic. 
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4. MATERIALS AND METHODS 
Virana Silethumam is one of the frequently encountered problem among young 
children in India. Hence it was proposed to study about the disease. A Protocol was 
prepared  and submitted before IEC & IAEC meeting, a copy of which was attached as 
Annexure-I. After obtaining approval from the commitee, the study Preclinical & clinical 
study on  Virana Silethumam (Acute Pharyngo tonsillitis) in children and the drug of 
choice was  malli chooranam was carried out in National Institute of Siddha. 
The ingredients for preparation of experimental formulation  malli chooranam 
was purchased from a well reputed country shop and raw drugs were authenticated by 
Herbal botanist. The medicine was prepared in Gunapadam lab of National institute of 
Siddha after proper purification.The prepared medicine was  also authenticated by the 
concerned Head Of The Dept for its completeness.   
Even though the drugs were pure herb safety of Malli Chooranam  by  Acute 
Toxicity study were done  in animal models according to WHO guidelines, 1993. For 
acute toxicity study  mice were used. 
After finishing the toxicity studies 40 cases were selected from the OPD & IPD of 
Kuzhandhai Maruthuvam Department, National Institute of Siddha. They were treated 
with the trial drug Malli Chooranam and observed for prognosis clinically. 
 
STUDY DESIGN & CONDUCT OF STUDY: 
Study Type:  An open clinical trial 
Study Place:  OPD & IPD of Ayothidass pandithar hospital,  
National Institute of Siddha , Tambaram sanatorium, Chennai-47. 
Study Period:  12 months 
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Duration of trial drug: 7 days 
Population and Sample: 
Inclusion criteria: 
 Age : 3-12 Years 
 Sex : Both male & female children 
 Children with symptoms of cough, sore throat, fever with malaise, swollen 
tonsils, odynophagia and headache. 
 Patients whose parents/guardian  are willing to sign the informed consent. 
 Patients who are willing to attend OPD once in 7 days/admitted in IPD of 
Ayothidass Pandithar Hospital. 
 Patients who are willing to provide blood, urine for lab investigations. 
Exclusion criteria: 
 Patient with known history of  Primary Complex, Diphtheria/whooping Cough, 
Allergic Rhinitis with Post nasal drip.  
 History of  congenital heart disease, seizure disoders. 
 Other serious illnesses based on Parental information and previous reports 
 
Sample size was 40 patients  
STUDY ENROLLMENT & CONDUCT OF THE STUDY: 
Patients reporting at the OPD with the clinical symptoms of sore throat, difficulty 
to swallow, headache, swollen tonsils, fever and signs of diffuse congestion, 
lymphadenitis, exudates, petechiae , tonsillar hypertrophy were examined clinically for 
enrolling in the study based on the inclusion and exclusion criteria.  
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The patients who were enrolled and their parents were informed about the study, trial 
drug, possible outcomes and the objectives of the study in the language and terms 
understandable to them.  
Afte
writing from their parents in the consent form (Form II). 
Complete clinical history, complaints and duration, examination findings were 
recorded in the prescribed Proforma (Form III). Screening Form- I was filled up; Form-
IV and Form V were used for assessment of symptoms & signs and for recording 
laboratory investigations respectively. Assessment were made on the basis of clinical 
features. 
Specific investigations of ASO, CRP were done in all patients in addition to the  
routine blood & urine investigations, before and after treatment.   
In the OPD, after initial tests and assessment, trial drug Malli Chooranam was 
given once for 7days after which clinical assessment was done and prognosis noted. In 
cases where there is need for further treatment due to incomplete improvement, 
medicines were given in the regular OPD of Ayothidasss  Pandithar hospital. The patients  
were observed for up to 14 days.  
In IP, the drug was provided each day for 7 days and prognosis noted after clinical 
assessment done on a daily basis. Laboratory  investigation was done before and after the 
course of the trial. At the end of the treatment, the patients were advised to visit the OPD 
for another two weeks for follow-up.  
ADMINISTRATION OF TRIAL DRUG: 
The drug was prepared by adhering to Standard operative procedure as per the 
protocol. It was dispensed in sealed polythene covers to prevent contamination. Patients 
were advised to take the trial drug, twice daily with milk in recommended doses (1.5 gms  
for 3-7 years/2.5 gms for 8-12 years). The patient compliance form was filled accordingly 
(Form-VII). Appropriate dietary advice (Form-
perfect understanding. The patients who were defauters were withdrawn from the trial. 
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DATA MANAGEMENT: 
After enrolling the patient in the study, a separate file for each patient was opened 
and all forms were filed in the file. The Data recordings were monitored for completion 
and adverse event. 
The following ASSESSMENT FORMS were used for data collection: 
 
FORM I  SCREENING & SELECTION PROFORMA 
 FORM II  CONSENT FORM 
FORM III  HISTORY PROFORMA  
 FORM IV  CLINICAL ASSESSMENT FORM 
FORM V  LABORATORY INVESTIGATION FORM 
FORM VI  ATION SHEET  
FORM VII  WITHDRAWAL FORM 
FORM VIII  ADVERSE REACTION  FORM 
FORM IX  DIETARY ADVICE FORM  
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5. RESULTS AND OBSERVATION 
 
For the clinical study, 40 cases were selected and treated in Ayothidoss Pandithar 
Hospital of National Institute of Siddha, Chennai. Results were observed with respect to 
the following criteria,  
 
1. Age distribution.  
2. Gender distribution  
3. Paruvam Distribution  
4. Diet Habits  
5. Socio  economic status  
6. Family history  
7. Personal habits 
8. Thinai reference  
9. Seasonal Reference  
10. Distribution of three thodam  
11. Udal kattugal reference  
12. Envagai Thervugal  
13. Neerkuri, Neikuri reference  
14. Etiological Factors 
15. Clinical features  
16. Hematological investigation  
17. Results after treatment. 
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AGE DISTRIBUTION: 
 
S.No AGE No. of Cases Percentage 
1 3 - 8 Years 27 68% 
2 9 - 12 Years 13 32% 
 Total 40 100% 
 
 
 
 
Out of the 40 cases taken for clinical trial, 27 (68%) cases were in the 3-8 years age 
group, 13(32%) cases were in the 9-12 years group. The doses of the drugs were given 
accordingly to these two groups.  
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GENDER DISTRIBUTION:  
 
S.No Sex No. of Cases Percentage 
1 Male 18 45% 
2 Female 22 55% 
 Total 40 100% 
 
 
 
In the 40 cases treated, 18 (45%) were male and 22 (55%) were female.  
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PARUVAM DISTRIBUTION:  
 
S.No Paruvam No. of Cases Percentage 
1 Kaappu & Chenkeerai ( 0  1yr) - - 
2 Varugai, Thalattu, Sappani (1- 3 yr) - - 
3 
Ambuli, Sitril, Chiruparai, Pethai (Female) 
Pillai paruvam(Male) (3 -6yrs) 
16 40% 
4 
Paethumbai, Mangai(Female), Chiru 
paruvam, Vaalibam(Male) (6-12 yrs) 
24 60% 
 
 
 
In 40 cases, 16 cases were in the 3-6 years age group and 24 were in 6-12 age group. 
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DIETARY PATTERN: 
 
S.No Diet Habits No. of Cases Percentage 
1 Vegetarian 5 10% 
2 Non  Vegetarian 35 90% 
 Total 40 100% 
 
 
 
Out of the 40 cases, 5(10%) cases were vegetarians and the rest 35(90%) cases had both 
vegetarian and non-vegetarian foods for diet. 
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SOCIO ECONOMIC STATUS 
 
 
 
In 40 cases, 4 were from poor, 8 from rich and the remaining 28 from middle income 
families. 
S.No Economic No. of Cases Percentage 
1 Poor 4 10% 
2 Middle class 28 70% 
3 Rich 8 20% 
 Total 40 100% 
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FAMILY HISTORY : 
S.No Family History No. of Cases Percentage 
1 Present 8 20% 
2 Absent 32 80% 
 Total 40 100% 
 
 
 
Out of the 40 cases, 8 cases (20%) had positive family history and the rest 32 (80%) had 
no family history or contacts. 
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PERSONAL HABITS: 
 
S.No Personal Habits No. of Cases Percentage 
1 Nail Biting 28 70% 
2 Thumb Sucking 4 10% 
3 Unhygienic Food Intake 8 20% 
4 Poor personal hygiene 12 30% 
5 Nocturnal Eneuresis 6 15% 
 
 
 
About 28 (70%) cases in the trial had the habit of nail biting, 12(30%) had poor personal 
hygiene, 8 (20%) cases had unhygienic food intake in outside eateries, 6(15%) had 
nocturnal eneuresis. 
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THINAI REFERENCE: 
 
S.No Thinai History No. of Cases Percentage 
1 Kurinji 2 5% 
2 Mullai - - 
3 Marutham 8 20% 
4 Neithal 30 75% 
5 Paalai - - 
 Total 40 100% 
 
 
In 40 cases, 30 (75%) cases were from Neithal nilam,8(20%) cases were from Marutham 
nilam and 2 (5%) were from kurinji nilam. 
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SEASONAL REFERENCE: 
S.No Season No. of Cases Percentage 
1 Kaarkaalam 19 47.5% 
2 Koothirkaalam 12 30% 
3 Munpanikaalam - - 
4 Pinpanikalaam -  
5 Elavenil Kalaam - - 
6 Mudhuvenil Kaalam 9 22.5% 
 Total 40 100% 
 
 
 
In the trial of 40 cases, majority of about 19(47.5%) cases were registered in kaar kalam, 
12(30%) during koothir kalam and 9(22.5%) in muduvenir kalam.  
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DISTRIBUTION OF THREE THODAM  
Table illustrating the derangement of  Vatham 
S.No Classification of Vatham No of cases Percentage 
1 Pranan 4 10% 
2 Abanan 5 12.5% 
3 Viyanan - - 
4 Uthanan 40 100% 
5 Samanan 40 100% 
6 Nagan 3 7.5% 
7 Koorrman 2 5% 
8 Kirukaran 5 12.5% 
9 Devathathan 8 20% 
10 Dhananjeyan - - 
 
 
In vatham, uthanan and samanan were affected in all 40 cases.  
Devathathan was found to be deranged in 8 cases. 
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Table illustrating the derangement of Pitham: 
 
S.No Classification of Pitham No of cases Percentage 
1 Analam 8 20% 
2 Ranjagam 7 18% 
3 Saathagam 0 0% 
4 Prasagam 0 0% 
5 Alosagam 0 0% 
 
 
 
In pitham, ranjagam was found to be affected in 8 (20%) cases and analam in 7 (18%) 
cases. 
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Table illustrating the derangement of Kabam: 
 
S.No Classification of Kabam No of cases Percentage 
1 Avalambagam - - 
2 Kilethegam 3 8% 
3 Pothagam - - 
4 Tharpagam - - 
5 Santhigam - - 
  
 
 
 
In kabam, only klethagam was affected in 4(10%) cases out of 40 cases.  
82 
 
UDAL KATTUGAL REFERENCE: 
S.No Types No of cases Percentage 
1 Saaram 40 100% 
2 Senneer 16 40% 
3 Oon 4 10% 
4 Kozhuppu 2 5% 
5 Enbu 0 0% 
6 Moolai 0 0% 
7 Sukkilam / Suronitham 0 0% 
 
 
 
Saaram was affected in all 40 cases, senneer in 16(40%), oon in 4(10%) and kozhuppu in 
2 (8%) of the cases. 
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ENVAGAI THERVUGAL: 
S.No Types No. of cases Percentage 
1 Naa 40 100% 
2 Niram 8 20% 
3 Mozhi 8 20% 
4 Vizhi 12 30% 
5 Sparisam 36 90% 
6 Malam 4 10% 
7 Moothiram 2 5% 
8 
Naadi: 
a. Pitha kabam 
12 30% 
b. Kaba pitham 10 25% 
c. Vatha pitham 18 45% 
 
 
 
 
 
Naa was affected in all 40 cases, vizhi in 12 cases, sparisam in 36 cases, mozhi, niram in 
8 case each, malam in 4 cases. Vatha pitham nadi was found in 18 cases. 
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NEERKURI, NEIKURI REFERENCE:  
 
S.No Types No of cases Percentage 
1 
NEERKURI 
Vaikol Niram 
Athi Manjal Niram 
36 
4 
90% 
10% 
 
 
2 
NEIKURI 
Spreading like snake 
Like Ring 
Like Pearl 
4 
8 
28 
10% 
20% 
70% 
 
The urine of 36 cases (90%) were in vaikol niram, whereas 4(10%) cases were athi 
manjal in colour. Kaba neer in 28 cases, pitha neer in 8 & vatha neer in 4 cases. 
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ETIOLOGICAL FACTORS : 
 
S.No Etiological factors 
No. of 
Cases 
Percentage 
1 Intake of cold stuffs, ice creams etc 18 45% 
2 Drinking impure water 8 20% 
3 
Congested dwelling places and unhygienic 
habits 
10 25% 
4 Familial incidence of Tonsillitis. 11 28% 
5 Cold air exposure 35 88% 
 
 
 
In etiological factors, most cases (88%) reported due to cold air exposure followed by 
intake of cold stuffs which was found in 45% cases. 
86 
 
CLINICAL FEATURES  
S.No Clinical features No of cases Percentage 
1 COUGH 36 90% 
2 FEVER 16 40% 
3 MALAISE 16 40% 
4 SORE THROAT 36 90% 
5 ODYNOPHAGIA 32 80% 
6 HEADACHE 12 30% 
7 ANTERIOR CERVICAL LYMPHADENITIS 31 78% 
8 DIFFUSE MUCOSAL CONGESTION 40 100% 
9 INFLAMMATORY EXUDATES 12 30% 
10 PETECHIAE 16 40% 
11 PUSTULES - - 
12 TONSILLAR HYPERTROPHY 36 90% 
 
 
Cough was the predominant symptom present in 36 cases out of 40 cases. 
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COUGH ANALYSIS: 
 
S.No COUGH Absent Mild Moderate Severe 
1 After Treatment 24 10 2 0 
2 Before Treatment 8 4 8 20 
 
 
 
The number of cases with severe cough reduced from 20 (before treatment) to 0 (after 
treatment).  The number of cases without cough increased from 8 to 24 after treatment. 
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DISEASE PROGNOSIS: 
 
S.No Clinical features Before Treatment After Treatment 
1 FEVER 16 1 
2 MALAISE 16 2 
3 SORE THROAT 36 0 
4 ODYNOPHAGIA 32 0 
5 HEADACHE 12 2 
 
 
 
The number of cases relieved of fever was 15 out of 16 & without malaise was 14 out of 
16 and headache was 10 out of 12. All cases with sore throat and odynophagia was 
relieved of their symptoms. 
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HEMATOLOGICAL INVESTIGATION: 
Erythrocyte Sedimentation rate (ESR/ hour) before treatment: 
 
 
S. No ESR/hour in mm No of cases Percentage 
1 10 and below 24 60% 
2 11 - 20. 12 30% 
3 21 and above 4 10% 
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Erythrocyte Sedimentation rate (ESR/ hour) after treatment: 
 
S. No ESR/hour in mm No of cases Percentage 
1 10 and below 33 83% 
2 11 - 20. 5 13% 
3 21 and above 1 3% 
4 31 and above 1 3% 
 
 
 
There is considerable reduction in groups of higher ESR and increase in groups of lower 
ESR, this proves the fact there is notable reduction in ESR levels on the whole.  
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RESULTS AFTER TREATMENT: 
 
S.No Results No. of Cases Percentage 
1 Good Relief 32 80% 
2 Moderate Relief 6 15% 
3 Mild Relief 2 5% 
 
 
 
Out of the 40 cases taken for trial, 32 cases showed good relief of the symptomatology, 6 
cases showed moderate relief and 2 cases showed mild relief. 
 
 
 
 


 Improvement in Clinical Symptoms of Viranasilethumam before and after treatment:  
 
 
  
1 D00197 R.Adhirai  5/F ++  - + - + - + - + - - -
2 C578 S.Buvaneswari 7/M ++ - - - + - + - - - - -
3 A74753 Dhivya 6/F +++ - - - - - + - + - - -
4 A67920 Manoj Kumar 12/F ++ - - - + - + - + - + -
5 C812 Loganathan 8/M - - - - + - + - + - + -
6 C813 Kavitha 5/F +++ + - - + - - - - - - -
7 B30437 Aruna 8/M ++ + - - - - + - + - - -
8 AI7116 P.Praveen 8/M - - + - - - + - + - + -
9 B68801 Adithya 5/M +++ ++ - - - - - - - - - -
10 C10512 G.Harini 10/F ++ - - - + - - - - - - -
11 B95484 Meena 7/M +++ - - - - - + - + - - -
12 C11569 Kavitha 6/F +++ - + - + - + - + - - -
13 C14461 Nithya 8/F +++ + - - - - + - - - - -
14 C14752 Priya 5/M - - - - - - + - + - - -
15 B30573 Kumar 5/F ++ - + - - - + - + - - -
16 C13458 Vidhya sagar 11/M - - - - + - - - - - + -
17 B93497 Thiyagu 6/M + - + - - - + - - - - -
18 C17508 R.S.Vineetha 3/M - - - - - - + - - - - -
19 C14883 Rajitha 11/M +++ + - - - - + - + - + -
20 C5628 S.Ruthrasree 4/F +++ - - - - - + - + - - -
21 C15496 Prem Kumar 12/M +++ ++ - - - - - - - - - -
22 C13571 Fazila 11/F ++ - - - - - + - + - - -
23 C15334 V.J.Amal 11/M ++ + - - - - - - - - - -
24 B71092 Sweety 6/F - - - - - - + - + - - -
25 A92212 Kalaivani 12/F ++ - + - - - + - + - + -
26 A91337 Rajalaksmi 9/F - - - - - - + - + - + -
27 C17611 Susinder 12/M + - + - - - - - - - - -
28 B61262 Lavanya 12/F +++ + - - - - - - - - - -
29 B74289 Vaishnavi 4 1/2/F +++ + - - - - - - + - - -
30 B53740 Srilekha 8/F +++ - - - - - + - - - - -
31 B94984 Prabaharan 9/M +++ + + - - - + - + - - -
32 B97822 A.Balaji 12/M - - - - - - + - - - - -
33 AR4362 C.Christy 11/F +++ + + - + - + - + - - -
34 799 Anburani 9/F +++ + + - + - + - + - + +
35 803 Ranjith 12/M ++ + - - + - + - + - + -
36 833 Kiruba 8/M +++ + + - + - + - + - - -
37 834 Nithin Prakash 4 1/2/M +++ + + - + - + - + - + -
38 858 Angel jovitha.L 6/F +++ - + - + - + - + - - -
39 864 Snegha 10/F +++ + + + + - + - + - - -
40 868 Prithivi 7/M ++ + + - + - + - + - - -
AT BT AT BT AT BT AT AT
ODYNOPHAGIA HEADACHE
BTBT AT BT
COUGH FEVER MALAISE SORE THROAT
AGE/
SEXName
OP/IP 
NOS.NO
Improvement in Clinical Symptoms of Viranasilethumam before and after treatment:  
 
 
1 D00197 R.Adhirai  5/F +++ + +++ + - - - - - - ++ +
2 C578 S.Buvaneswari 7/M + - +++ + - - - - - - + +
3 A74753 Dhivya 6/F + + +++ + - - - - - - ++ +
4 A67920 Manoj Kumar 12/F ++ + +++ + - - - - - - + +
5 C812 Loganathan 8/M +++ + +++ ++ + - - - - - +++ +++
6 C813 Kavitha 5/F ++ + +++ + - - - - - - ++ ++
7 B30437 Aruna 8/M + + ++ + - - - - - - + +
8 AI7116 P.Praveen 8/M +++ ++ +++ + + - + - - - ++ ++
9 B68801 Adithya 5/M ++ ++ +++ - + - - - - - +++ +++
10 C10512 G.Harini 10/F ++ + +++ - - - - - - - ++ +
11 B95484 Meena 7/M +++ + +++ + + - + - - - ++ +
12 C11569 Kavitha 6/F ++ + +++ + + - + - - - + -
13 C14461 Nithya 8/F +++ + +++ + - - - - - - + +
14 C14752 Priya 5/M - - +++ + + - - - - - +++ ++
15 B30573 Kumar 5/F ++ - +++ - - - - - - - ++ +
16 C13458 Vidhya sagar 11/M ++ - +++ - - - - - - - + -
17 B93497 Thiyagu 6/M - - +++ + - - + - - - + -
18 C17508 R.S.Vineetha 3/M ++ + +++ + - - - - - - ++ ++
19 C14883 Rajitha 11/M ++ + +++ + - - - - - - + +
20 C5628 S.Ruthrasree 4/F +++ + +++ - - - - - - - ++ +
21 C15496 Prem Kumar 12/M ++ + +++ ++ + - - - - - ++ ++
22 C13571 Fazila 11/F - - +++ + + - + - - - ++ ++
23 C15334 V.J.Amal 11/M + + +++ + + + - - - - ++ ++
24 B71092 Sweety 6/F ++ - +++ - - - - - - - + -
25 A92212 Kalaivani 12/F + + +++ ++ + - - - - - + +
26 A91337 Rajalaksmi 9/F - - +++ ++ - - - - - - +++ +++
27 C17611 Susinder 12/M ++ + +++ + - - - - - - ++ +
28 B61262 Lavanya 12/F ++ - +++ - + - + - - - ++ ++
29 B74289 Vaishnavi 4 1/2/F ++ + +++ - + - + - - - +++ +++
30 B53740 Srilekha 8/F ++ + +++ + - - - - - - + -
31 B94984 Prabaharan 9/M - - +++ + - - - - - - + -
32 B97822 A.Balaji 12/M - - +++ + - - - - - - ++ ++
33 AR4362 C.Christy 11/F +++ + +++ + - - - - - - + -
34 799 Anburani 9/F - - +++ ++ + - - - - - +++ +++
35 803 Ranjith 12/M - - +++ - + - + - - - ++ +
36 833 Kiruba 8/M +++ ++ +++ ++ + - - - - - ++ ++
37 834 Nithin Prakash 4 1/2/M +++ + +++ + - - - - - - + -
38 858 Angel jovitha.L 6/F - - +++ + - - - - - - ++ ++
39 864 Snegha 10/F + - +++ + + - - - - - ++ +
40 868 Prithivi 7/M + - +++ - + - - - - - + -
AT BT ATBT AT BT AT
PETECHIAE PUSTULES TONSILLAR HTEXUDATES
BT AT
OP/IP 
NO Name BT AT BT
AGE/
SEXS.NO
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6.  DISCUSSION 
Virana silethumam  is one of the recurrent upper respiratory tract infections seen 
in children due to deranged silethumam. It more or less correlates with acute Pharyngo-
tonsillitis. The management for this disease in conventional therapy is using antibiotics or 
surgical procedure like tonsillectomy. Both have demerits. Hence a herbal formulation 
malli chooranam  is taken for the study in the management of Virana silethumam. 
Most of the ingredients of malli chooranam have  hot, dry thanmai & kaarpu  
vibagam which act on deranged silethumam. Also demulcent property of the drug 
ingredients acting on the vitiated Pitham. 
Scientifically many drug ingredient of malli chooranam have antibacterial 
activity. Most cause for this disease in young children is bacteria. Some drugs have 
antiinflammaory, analgesic, antipyretic, antioxidant properties. All these properties are 
beneficial for treating the illness. 
Eventhough the trial drug  was  purely herbal origin for safety toxicity studies 
were done. No toxicity effect was found in the preclinical study. And also there were no 
adverse drug effects among trial subjects reported during or after clinical trial.  
In the study 40 cases showing clinical features of Virana silethumam were 
admitted to trial based on the inclusion criteria. History-taking, Clinical assessment, 
investigations, diagnosis were done based on Siddha and modern literatures. The 
available data was entered into individual case proforma. The patients were treated with 
Malli chooranam and recommended dietary pattern. Clinical observations were made on 
8th and 14th day of trial. 
From the results and observations dealt in previous chapters, clinical discussions 
are made out.  
A slight dominance (68%)  in the age group of 3-8 years was observed in the 
study which is in accordance with the author of Pediatric otolaryngology, John Evans. In 
the study with 90% enrolled being non-vegetarians  literature quotes excessive eating & 
frequent intake of sour, sweet, pungent foods as causes of excessive phlegm formation. 
Though over crowding, poor sanitation & malnutrition are predisposing factors only 28% 
of the subjects were from poor strata. 
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70% of the cases had nail biting and 30% did not have the habit of washing hands before 
eating, 20% eating uhygeinic foods all predisposing to infections. 
Literature states, pearl like static type of Neikuri in kaba illnesses; in the study, 
around 70% of the cases showed kaba neer. In line with the etiology quote in siddha 
texts, cold air exposure was found to be the etiology in 88% of the cases which was 
followed by intake of cold stuffs in 45% cases.  
With reference to three thodams, 
In vatham: uthanan & samanan were affected in all cases, devedhathan in 20% cases, 
abanan in 13% cases, and 14% showed deranged kirukaran. Nagan in 8% & koorman was 
affected in 5% cases each. 
In pitham: ranjagam was affected in 18% cases, analam in 20% cases. 
In kabam: klethagam was found to be affected in 8% cases. 
 
The clinical features of Virana silethumam correlate with the general clinical 
manifestations of Acute Pharyngo-tonsillitis. 
In accordance with the Clinical manifestations of Virana silethumam, sorethroat 
was found in 90% cases, lymphadenitis accompanied with fever was present in 78% of 
cases,  cough was the major symptom in 90% cases, difficulty in swallowing due to 
throat ulcer was present in 80% cases. These cases were diagnosed to have Acute 
Pharyngo-tonsillitis according to modern parameters. 
 
Regarding the symptoms, 
 24 Cases were completely relieved of cough after treatment, irrespective of the 
severity with which they first reported.  20 cases with severe cough and 
expectoration before treatment had only occasional dry cough at the end of 
treatment. 
 16 Cases reported with fever (either intermittent or continous), out of which 15 
cases were relieved of fever at the end of course.  
 16 Cases with malaise showed improvement. 
 36 Cases with sore throat and 32 cases with odynophagia were relieved of their 
symptoms at the end of treatment. 
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 All 12 Cases except two were relieved of their headache. 
Regarding the signs, 
 Exudates in 12 cases and petechiae in 16 cases were absent at the end of trial. 
 In 40 cases with diffuse congestion, 10 cases showed no congestion, 6 cases with 
moderate & 24 cases was with mild congestion at the end of treatment. 
 During the trial, 9 cases showed severe lymphadenitis, 15 with moderate , 7 with 
mild lymphadenitis. At the end of the trial, 3 cases showed moderate & 21 cases 
with mild lymphadenitis. 16 cases had no lymphadenitis as against the earlier 9 
cases before treatment.  
 Reduction in tonsillar hypertrophy was not achieved to greater extent as expected. 
1 case showed reduction in G3 to G2., 6 cases showed reduction from G2  to G1 , 9 
cases showed reduction in G1 to G0 .  Significant reduction in tonsillar size was 
observed only during the earlier stages such as G1 & G2  but not in later stages 
such as G3 .  
 There was significant reduction in ESR in about 19 cases. 
In addition, patient reported improvement in other symptoms such as constipation, 
stomach ache, rhinitis. Irritability and sleeplessness was relieved in younger children. The 
The drug improves appetite, general sleep, and controls progression of URTI to LRTI. 
 
On basis of Siddha & Modern reasoning, improvement in the clinical features in trial 
subjects may be due to  
 Hot, dry thanmai & kaarpu vibagam of the drug ingredients acting on the 
deranged Silethumam. 
 Demulcent property of the drug ingredients acting on the vitiated Pitham. 
 Anti-microbial activity of the Eugenol in the drug is effective against 25 genera of 
bacteria and virus. 
 Significant anti-inflammatory, analgesic, anti-pyretic actions of the drug. 
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7. SUMMARY 
The aim of the study is to study the efficacy of Malli chooranam for the 
management of virana silethumam with reduction of clinical symptoms.The Siddhars 
with their tremendous foreseeing and unfathomable knowledge have clearly mentioned 
the symptomatology, etiology and treatment of Virana silethumam. 
The acute toxicity study confirmed the safety of the drug and dosing among 
pediatric population. 
 For the clinical study, 40 cases were selected from Department of Kuzhanthai 
maruthuvam of Ayothidass Pandithar Hospital of National Institute of Siddha, Chennai. 
Clinical diagnosis was done by means of Siddha and Modern Methodology. 
The trial subjects were treated with Malli chooranam  twice daily  according to 
the age group. Based on the reporting patients, the improvement in the condition of the 
patients was observed from the second day itself. Within 4 days, patient showed good 
relief in symptoms. Observations made during the clinical study showed that the trial 
drug was clinically effective. 
Clinically, Malli chooranam  had significant analgesic, anti-pyretic and anti-
inflammatory action enough to produce clinical effects.  
In clinical observation, it was found that 80% of the patients showed good relief 
in signs and symptoms. Further , there was no development of any adverse drug reactions 
in the pediatric population. 
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8. CONCLUSION 
Clinical trial with Malli chooranam showed remarkably good results in the 
management of Virana silethumam without producing any adverse drug effects. 
A safe herbal formulation that can be which is clinically efficacious in treating 
even acute inflamed conditions like acute pharyngo - tonsillitis. The drug can be safely 
administered to small infants in the event of recurrent episodes due to climatic changes..  
Thus,  it is concluded that in a developing countries like ours, the treatment with 
Malli chooranam will be safe, efficacious and easily available with cost effective 
ingredients for the welfare of pediatric population.  
 
 
ANNEXURE-I 
PROTOCOL 
 
TITLE: 
                         Preclinical & clinical study on 
Pharyngo tonsillitis) in children and the drug of choice is MALLI CHOORANAM. 
BACKGROUND: 
           Siddha, one of the oldest Indian Systems of Medicine aims at providing wholesome 
cure to all ailments a man is deposed with. It is very potent & unique when compared 
with other traditional systems in existence. In siddha system diseases are classified into 
4448 types on basis of the three humours ie, Vatham(wind), Pitham(fire), 
Kabam(phlegm) constituting the fundamentals of this system. According to Classical 
Siddha literatures derangement of kabam can lead to 20 different types of diseases, of 
which Virana silethumam is one of them. 
        The clinical picture of virana silethumam includes sore throat with mucous and 
pustular exudates, swelling of anterior and posterior cervical area with fever, rigor, 
burning sensation all over the body, cough, crying out of severity, ulceration of throat and 
tongue. The symptomatology of Virana silethumam is grossly comparable with that of 
Acute Pharyngo-tonsillitis. 
               Acute Pharyngo-tonsillitis caused by Streptococcus species typically occurs in 
children aged 5-15 years ( Chobby et al,  Mar 2009). Around the world sore throat is one 
of the very common recurrent illnesses in children of which 37% being diagnosed as 
bacterial acute Pharyngo-tonsillitis. 
                  Antibiotics  kill healthy intestinal bacteria which helps to keep the immune 
system healthy. Also administration of antibiotics and analgesics to children may result in 
the development of higher resistance (Arora et al,1999
etc.,. To avoid the unwanted administration of antibiotics in children which may cause  
many adverse effects I wish to conduct a detailed study about  virana silethumam through 
malli chooranam, a herbal formulation .  
The study drug has essential oil containing  predominantly  derivatives of Eugenol 
(Hattori et al 1986), which act potently against 25 genera of bacteria (including 
Streptococcus, B.subtilis) involved in causing pharyngo tonsillitis (Ghelardini et al 
2007). The drugs Coriandrum sativum, Cuminum cyminum, Nigella sativa possess 
antibacterial activity. Glycyrrhiza glabra  posses anti-inflammatory and anti-allergic 
activity. 
AIM & OBJECTIVES:  
Primary objective: 
 To evaluate the reduction of clinical symptoms. 
Secondary objective:  
 To evaluate the Safety of Malli Chooranam in the treatment of  Virana 
silethumam ( Acute Phayngo-Tonsillitis)  through Acute and Sub acute Toxicity 
in animal models. 
 To evaluate siddha co-factors in the course of treatment. 
 To correlate between Virana silethumam and Acute Pharyngo-tonsillitis. 
MATERIALS AND METHODS 
STUDY DESIGN & CONDUCT OF STUDY: 
Study Type:  An open clinical trial 
Study Place:  OPD & IPD of Ayothidass pandithar hospital,  
National Institute of Siddha , Tambaram sanatorium, Chennai-47. 
Study Period: 12 months 
 
 
Population and Sample:.   
 The population consists of patients attending the OPD & IPD of Ayothidoss 
Pandithar Hospital, National Institute of Siddha, Chennai-47. 
 The sample consists of 3 -12 years age group fulfilling the inclusion criteria.  
Sample size: 40 patients 
SUBJECT SELECTION: 
                As and when patients reporting with symptoms of inclusion criteria will be 
subjected to screening test & documented using screening Proforma. 
INCLUSION CRITERIA: 
1. Age : 3-12 Years 
2. Sex : Both male & female children 
3. Children with symptoms of cough, sore throat, fever with malaise, swollen 
tonsils, odynophagia and headache. 
4. Patients whose parents/guardian  are willing to sign the informed consent. 
5. Patients who are willing to attend OPD once in 7 days/admitted in IPD of 
Ayothidass Pandithar Hospital. 
6. Patients who are willing to provide blood, urine for lab investigations. 
 EXCLUSION CRITERIA: 
 Patient with known history of  Primary Complex, Diphtheria/whooping Cough, 
Allergic Rhinitis with Post nasal drip.  
 H/O Congenital heart disease, seizure disoders. 
 Other serious illnesses based on Parental information and previous reports.  
 
 
 
WITHDRAWAL CRITERIA: 
 Occurrence of serious adverse effects which may/may not be related to trial drug. 
 Poor patient compliance. 
 Patient turned unwilling to continue in the course of clinical trial. 
 Exacerbation of symptoms 
Name of the Trial Drug: Malli Chooranam 
STANDARD OPERATING PROCEDURE: 
INGREDIENTS: 
1. Parangi chakkai (smilax china)   35gms 
2. Athimathuram (Glycyrrhiza glabra)  35gms 
3. Karunseeragam (Nigella sativa)  35gms 
4. Seeragam (Cuminum cyminum)  35gms 
5. Pilapu seeragam Shah-zirah (Carum bulbocastum)  35gms  
6. Elam (Elettaria cardomomum)  35gms 
7. Sannalavanga pattai (Cinnamomum verum )  35gms 
8. Kirambu (Syzygium aromaticum )- 35gms 
9. Viraiilla thiraichai (Vitis vinifera )  35gms 
10. Thania (Coriandrum sativum)  315gms 
 
 
 
 
I ) SOURCE OF TRIAL MEDICINE: 
                     The ingredients for preparation of experimental formulation  MALLI 
CHOORANAM would be purchased from a well reputed country shop and raw drugs 
are authenticated by the help of   Dept HOD and Herbal botanist and with Department of 
Gunapadam. The  medicine  will be  prepared in Gunapadam lab of National institute of 
Siddha after proper purification.The prepared medicine  also authenticated by the 
concerned Head Of The Dept for its completeness.   
II ) METHOD OF PURIFICATION & PREPARATION: 
Malli Chooranam  
Ref: Chikicha ratna deepam ,Pg.no. 120 
PURIFICATION METHODS: 
Parangisakkai: Initially the drug is dried & made into fine powder.Then milk is taken in a 
earthen ware vessel & its mouth is covered with cloth.Then the powder is is kept on the 
cloth & it is covered with another earthen ware vessel.It is then boiled for 3 hours.The 
resultant powder is dried in sunlight & grinded.   
Athimathuram: Wash with  clean water & peel the outer layer.Then cut into small  pieces 
and dry  in sunlight. 
Karunjseeragam:Remove the dust & dry it in sunlight.Then fry to golden brown colour. 
Seeregam: Remove the dust & dry  in sunlight. 
Pilappu seeragam: Dried in sunlight. 
Cardamom:Dried in sunlight. 
 Lavangapattai :  Dried in sunlight 
 Kirambu :     Dried in sunlight. 
Thiratchai: Remove the dust. 
Kothamalli: Tie it in a cloth,and boil  in hot water or lime juice. Then dry  in sunlight.  
 
 
Method of preparation: 
        All the raw drugs given above except coriander seed are fried until to  golden brown 
colour.   Then the drugs are ground into a fine powder. It is filtered by using a fine cloth 
(Vasthirakaayam). Now equal amount of sweet candy powder is added with the 
chooranam and stored in air tight container. 
DOSE :  Arai thola ( 6gms ) 
 1.5 grams  for 3 to 7 years of age, twice daily 
 2.5 grams for 8 to 12 years of age, twice daily  
(subjected to the verification of the therapeutic dose in animal models by toxicity studies) 
ADJUVANT:   Milk 
DRUG DURATION: 7 days  
INDICATIONS: Thondaipun, , Thondaikammal, Vikkal, Vaanthi, Kaatthadaippu  
                              Arosikam, Athika viyarvai viduthal, Kaikaal erichal. 
III )DRUG STORAGE:  
The trial drug  Malli Chooranam is stored in clean and dry wide mouthed glass bottle. 
IV )DISPENSING:   
The Malli chooranam is given in powder form as separate pockets of individual dose in a 
ziplock cover. 
ASSESSMENTS & TEST : 
 CLINICAL ASSESSMENT 
 ROUTINE INVESTIGATION 
 SPECIFIC INVESTIGATION 
 SIDDHA ASSESSMENT 
CLINICAL ASSESSMENT: 
SYMPTOMS: 
1. Cough 
2. Fever, malaise and rigor  
3. Sore throat with mucous and pustular exudates 
4. Odynophagia 
5. Headache 
6. Swollen tonsils 
7. Swelling of anterior and posterior cervical area lymph nodes 
8. Burning sensation all over the body 
9. Crying out of severity of disease. 
 
 ROUTINE INVESTIGATIONS: 
 BLOOD INVESTIGATIONS: 
1. Haemoglobin 
2. Total WBC Count 
3. Differential Count 
4. Total RBC count. 
5. Erythrocyte Sedimentation Rate 
 
URINE EXAMINATION:  
1. Albumin  
2. Deposits  
 
SPECIFIC INVESTIGATION: 
1. ASO Titre 
2. CRP 
3. Throat swab(if required) 
 SIDDHA ASSESSMENT: 
1. Nilam 
2. Kaalam 
3. Uyirthathukal 
4. Udalthathukal 
5. Envagai thervu 
6. Neerkuri 
7. Neikuri 
 METHODOLOGY: 
STUDY ENROLLMENT: 
In the Phase II study, patients reporting at the OPD with the clinical symptoms of sore 
throat, odynophagia, headache, swollen tonsils, fever will be examined clinically for 
enrolling in the study based on the inclusion and exclusion criteria.  
The patients who are to be enrolled would be informed about the study, trial drug, 
possible outcomes and the objectives of the study in the language and terms 
understandable to them. 
obtained in writing from their parents in the consent form. 
number of the study, Address, Phone number and Doctors phone number etc. will be 
given, so as to report easily should any complications arise. 
Complete clinical history, complaints and duration, examination findings-- all would be 
recorded in the prescribed Proforma in the history and clinical assessment forms 
separately. Screening Form- I will be filled up. Form III,   Form IV and Form V will be 
and laboratory investigations respectively. 
Patient will be advised to take the trial drug and appropriate dietary advice  would be 
 
CONDUCT OF THE STUDY: 
          7 days. On 
the 8th day patient will be  requested to attend the OPD for clinical assessment and it will 
informant are requested to bring back the un-consumed trial drug if any. For IP patients 
the drug will be provided daily and prognosis  noted. Laboratory investigations  will be 
done on 0 day & 15th day of the trial are recorded.  After the completion of the treatment, 
the patient is advised to visit the OPD  for another 1 months for follow-up. If any trial 
patient who fails to collect the trial drug on the prescribed day but wants to continue in 
the trial from the next day or two, he/ she will be allowed, but defaulters of one week and 
more will not be allowed to continue and be withdrawn from the study with fresh case 
being inducted. 
 DATA MANAGEMENT: 
 After enrolling the patient in the study, a separate file for each patient will be 
opened and all forms will be filed in the file. Study No. and Patient No. will be 
entered on the top of file for easy identification. Whenever study patient visits 
OPD during the study period, the respective patient file will be taken and 
necessary recordings will be made at the assessment form or other suitable 
form. 
 The screening forms will be filed separately. 
 The Data recordings in all forms will be monitored and scrutinized by HOD, 
Dept of kuzhanthai maruthuvam . 
 Data analysis will be done with the help of Senior Research Officer (statistics) 
of NIS. 
  OUTCOME : 
  PRIMARY OUTCOME: 
Will be assessed by scoring in reduction of clinical symptoms before and after  treatment.  
SECONDARY OUTCOME:  
Assessed by   
  1. Reduction of ESR  
2. Reversal of Neutrophil leucocytosis. 
ADVERSE EFFECT/SERIOUS EFFECT MANAGEMENT:If the trial patient 
develops any adverse reaction, he/she would be immedietly withdrawn from the trial and 
proper management will be given in OPD of National institute of siddha and the same 
will be reported to regional pharmacovigilance centre. 
ETHICAL ISSUES: 
1. To prevent any infection, while collecting blood sample from the patient, only 
disposable syringes, disposable gloves, with proper sterilization of lab equipments 
will be used.                          
2. No other external or internal medicines will be used. There will be no 
infringement on the rights of patient.    
3. The data collected from the patient will be kept confidentially.  
4. The patient will be informed about the diagnosis, treatment and follow-up.  
5. Informed consent will be obtained from the guardian of the patient after 
explaining in the understandable language to the patient and guardian. 
6. After the consent from concerned guardian of the patient (through consent form) 
they will be enrolled in the study.  
7. Treatment would be provided free of cost.  
8. In conditions of treatment failure, adverse reactions, patients will be given 
alternative treatment at the National Institute of Siddha with full care throughout 
the end.               
9. The patients with exclusion criteria not included in the trial will be treated as 
regular cases in the OPD of Ayothidass Pandithar Hospital.  
 ASSESSMENT FORMS 
FORM I - SCREENING & SELECTION PROFORMA 
 
 FORM  II - CONSENT FORM 
 
FORM  III - HISTORY PROFORMA  
 
 FORM IV - CLINICAL ASSESSMENT FORM 
 
FORM  V -LABORATORY INVESTIGATION FORM 
 
FORM VI -  SHEET  
 
FORM VII     - WITHDRAWAL FORM 
 
FORM VIII - ADVERSE REACTION  FORM 
 
FORM  IX     -   DIETARY ADVICE FORM  
 ANNEXURE-II 
PROFORMA 
 
NATIONAL INSTITUTE OF SIDDHA, CHENNAI-47. 
AYOTHIDOSS PANDITHAR HOSPITAL 
DEPARTMENT OF KUZHANDHAI MARUTHUVAM 
 
A STUDY ON VIRANA SILETHUMAM (ACUTE PHARYNGO-TONSILLITIS) 
 IN CHILDREN 
 
FORM I - SCREENING FORM 
 
 
 1. SI NO:______     2 OP /IP NO:_________     3. NAME: _____________   4.  RELIGION: H / C / M / O      
 
 5. AGE: ______      6.GENDER: M  F         
 
 8. INCOME: _______    9. INFORMANT: ___________   10. RELIABILITY: ___________ 
 
 
INCLUSION CRITERIA:      YES         NO 
1. COUGH   
2. FEVER       
3. MALAISE                 
4. SORE THROAT        
5. DIFFICULTY TO SWALLOW      
6. HEADACHE         
7. SWOLLEN TONSILS      
8. LAB INVESTIGATIONS-WILLING 
 
 
EXCLUSION CRITERIA: 
 
1. PRIMARY COMPLEX 
2. DIPHTHERIA 
3. CONGENITAL HEART DISEASES 
4. ALLERGIC RHINITIS WITH POST 
       NASAL DRIP 
5. OTHER SERIOUS ILLNESSES 
 
 
 
 
ADMITTED TO TRIAL:                              
IF YES, SERIAL NUMBER:     
 
 
 
 
SIGNATURE OF INVESTIGATOR:   
SIGNATURE OF LECTURER:    
DATE: 
 
 
 
NATIONAL INSTITUTE OF SIDDHA, CHENNAI-47. 
AYOTHIDOSS PANDITHAR HOSPITAL 
DEPARTMENT OF KUZHANDHAI MARUTHUVAM 
 
A STUDY ON VIRANA SILETHUMAM (ACUTE PHARYNGO-TONSILLITIS) 
 IN CHILDREN 
 
 
FORM II - CONSENT FORM 
 
CERTIFICATE BY INVESTIGATOR 
 
I certify that I have disclosed all details about the study in the terms readily 
understood by the parent. 
 
 
 
Date:       Signature: 
       Name: 
 
 
 
CONSENT OF THE INFORMANT: 
 
 I have been informed to my satisfaction, by the attending physician, the purpose 
of the clinical trial, and the nature of the drug treatment and follow-up including the 
laboratory investigations to be performed to monitor and safeguard my son/daughter 
body functions. 
 
I am aware of my right to opt out of the trial to my son/daughter at any time 
during the course of the trial without having to give the reasons for doing so. 
 
I, am exercising my free power of choice, hereby give my consent to include my 
in the treatment of 
Virana Silethumam (Acute Phayngo-  
 
 
      Name of the patient: 
Date:       Signature of Parent/guardian: 
Station:     Name: 
      Signature of Witness: 
      Name 
 
¿¢ÚÅÉò¾¢ý ¦ÀÂ÷ : §¾º¢Â º¢ò¾ ÁÕòÐÅ ¿¢ÚÅÉõ 
«§Â¡ò¾¢¾¡º÷ ÀñÊ¾÷ ÁÕòÐÅÁ¨É,  
¦ºý¨É-47. 
    
´ôÒ¾ø ÀÊÅõ. 
    
¬öÅ¡ªÃ¡ø º¡ýÈª¢ì¸ôÀð¼Ð. 
  
¿¡ý ­ó¾ ¬ö¨Å ÌÈ¢ò¾ «¨ÉòÐ Å¢ÀÃí¸¨ªÔõ §¿¡Â¡ª¢Â¢ý 
¦Àü§È¡÷/À¡Ð¸¡ÅÄÕìÌ ÒÃ¢Ôõ Å¨¸Â¢ø ±ÎòÐ¨Ãò§¾ý ±É 
¯Ú¾¢Âª¢ì¸¢§Èý. 
 
 
§¾¾¢:        ¨¸¦Â¡ôÀõ: 
­¼õ:        ¦ÀÂ÷: 
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ÀÃ¢§º¡¾¨É¸û ÀüÈ¢Ôõ ¾¢Õô¾¢ «ª¢ìÌõ Å¨¸Â¢ø ¬ö× ÁÕòÐÅÃ¡ø Å¢ªì¸¢ì 
ÜÈôÀð¼Ð. 
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§ÅñÎÁ¡É¡Öõ ­ó¾ ¬ö¨Å Å¢ðÎ ±ý ÌÆó¨¾¨Â Å¢ÎÅ¢òÐ ¦¸¡ûÙõ 
¯Ã¢¨Á¨Â ¦¾Ã¢ó¾¢Õì¸¢§Èý. 
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º¢§ÄòÐÁ §¿¡öìÌ ÁøÄ¢ ÝÃ½ò¾¢ý ÀÃ¢¸Ã¢ôÒò ¾¢È¨Éì ¸ñ¼È¢Ôõ 
¬öÅ¢üÌ ±ÉÐ ÌÆó¨¾¨Â ¯ðÀÎò¾ ´ôÒ¾ø «ª¢ì¸¢§Èý. 
 
 
        §¿¡Â¡ª¢Â¢ý ¦ÀÂ÷: 
§¾¾¢:           ¦Àü§È¡÷/À¡Ð¸¡ÅÄÃ¢ý ¨¸¦Â¡ôÀõ: 
­¼õ:               ¦ÀÂ÷: 
              º¡ðº¢Â¢ý ¨¸¦Â¡ôÀõ: 
 : 
       
 
 
       NATIONAL INSTITUTE OF SIDDHA, CHENNAI-47. 
AYOTHIDOSS PANDITHAR HOSPITAL 
DEPARTMENT OF KUZHANDHAI MARUTHUVAM 
A STUDY ON VIRANA SILETHUMAM (ACUTE PHARYNGO-TONSILLITIS) 
 IN CHILDREN 
FORM III -  PROFORMA 
 
1. SI NO:______     2 OP /IP NO:_________     3. NAME: _____________   4.  RELIGION: H / C / M / O      
5. AGE: ______      6.GENDER: M  F        
8. INCOME: _______ 9. POSTAL ADDRESS: ______________________________________ 
____________________________________________________________________________ 
10. INFORMANT: _______________ 11.CONTACT NUMBER: __________________. 
 
12. COMPLAINTS AND DURATION: 
 
 
 
13. HISTORY OF PRESENT ILLNESS: 
 
 
14. HISTORY OF PAST ILLNESS: ...................................... YES  NO   
 
 A.JAUNDICE:           
 B.SEIZURES:      
 C. PRIMARY COMPLEX 
 D.CHRONIC PULMONARY DISORDER 
 E. DEVELOPMENTAL DELAY 
 F.OTHERS (PLS SPECIFY) _______________________________________________________ 
 
15. FAMILY HISTORY: 
 
16. PROPER IMMUNIZATION HISTORY: 
 
17. GENERAL HABITS: 
 
A.NAIL BITING                                  
B.THUMB SUCKING                                                           
C.PICA          
D.UNHYGIENIC FOOD INTAKE       
   (ROADSIDE EATERIES)  
E.POOR PERSONAL HYGIENE 
F.NOCTURNAL ENEURESIS         
 
            NORMAL         AFFECTED 
 
G. APPETITE          _______ 
 H.TYPE OF FOOD GIVEN:    VEG        NVEG  MIXED  
 I. BOWELS:         _______ 
 J. MICTURITION:             _______ 
 K. SLEEP         _______ 
  
 
 
 
 
18.GENERAL EXAMINATION: 
 A.HEIGHT (IN Cms)      _____________ 
 B.WEIGHT (IN Kgs)      _____________ 
 C.BMI:                _______ 
 D.TEMPERATURE (F)    _______ 
 E. HEART RATE _______/Min 
 F.PULSE RATE  _______/Min 
 G.RESPIRATORY RATE _______/Min 
 H. BLOOD PRESSURE _______mm/Hg 
            YES               NO 
I. PALLOR      
 J.ICTERUS 
 K.CYANOSIS 
 L.CLUBBING 
 M. LYMPHADENOPATHY 
 N. PEDAL EDEMA 
 O. JUGULAR VENOUS PULSATIONS 
 P. CONGENITAL ABNORMALITIES 
 
19.CLINICAL ASSESSMENT: 
 A.COUGH         If yes _______ 
 B.FEVER             If yes _______ 
 C.MALAISE          
 D.SORE THROAT       
 E.DIFFICULTY TO SWALLOW 
 F.HEADACHE 
 G. ANTERIOR CERVICAL 
     LYMPHADENITIS 
 H.DIFFUSE MUCOSAL CONGESTION 
 I. INFLAMMATORY EXUDATES 
 J. PETECHIAE 
 K. PUSTULES 
 L.TONSILLAR HYPERTROPHY       __        ________             
M.OTHERS___________________________      
 
                             
  
20. EXAMINATION OF RESPIRATORY SYSTEM: 
 INSPECTION: _______________________________________________________ 
 PALPATION: ________________________________________________________ 
 PERCUSSION: _______________________________________________________ 
 AUSCULTATION: ____________________________________________________ 
 
21. EXAMINATION OF OTHER SYSTEMS: 
 A.CARDIOVASCULAR SYSTEM:       ________________________ 
 B. ABDOMEN          ________________________ 
 C. CENTRAL  NERVOUS SYSTEM  ________________________ .  
22. OTHER ASSESSMENTS : 
 A.NILAM: 
          KURINJI                 MULLAI               MARUTHAM             NEITHAL          PAALAI  
 
B.KAALAM: 
          KAAR         KOOTHIR  MUNPANI       PINPANI       ILAVENIR    MUDUVENIR  
 
C.YAKKAI: 
            VALI                    AZHAL               IYAM               
           VALI AZHAL      VALI IYAM       AZHAL VALI    
           AZHAL IYAM           IYA VALI       IYA AZHAL  
 
D. GUNAM: 
         SATHUVAM       RASATHAM        THAMASAM    
 
   NORMAL       AFFECTED     NORMAL        AFFECTED 
E.PORI:             PULAN:  
MEI               UNARVU                  
VAAI               SUVAI                        
KANN               PAARVAI                  
MOOKU              MOPPAM                      
SEVI               KETTAL                  
 
F.KANMENDRIYAM:            KANMAVIDAYAM:  
KAI               THAANAM               
KAAL               KAMANAM              
VAAI               VASANAM               
ERUVAAI              VISARKAM                  
KARUVAAI              ANANDAM               
G.UYIR THATHUKKAL           NORMAL        AFFECTED 
    1.VATHAM: 
 PRANAN 
ABANAN     
UTHANAN 
VIYANAN 
SAMANAN 
NAGAN 
KOORMAN 
KIRUKARAN 
DEVADHATHAN 
DHANANJEYAN 
  2.PITHAM: 
 ANALAM 
 RENJAGAM 
 SATHAGAM 
 PRASAGAM 
 ALOSAGAM 
  3.KAPHAM: 
 AVALAMBAGAM 
 KILETHAM 
 POTHAGAM 
 THARPAGAM 
 SANTHIGAM 
  
H.UDAR THATHUKKAL 
 SARAM          
 SENNEER     
 OON 
 KOZHUPPU 
 ENBU 
 MOOLAI 
 SUKKILAM/ 
 SURONITHAM 
 
 
 
I.ENVAGAI THERVUGAL               
                       NORMAL         AFFECTED 
 1.NAA: 
       NIRAM:         ______ 
      THANMAI:         ______ 
      SUVAI:         ______ 
 2.NIRAM:                                                                      ______ 
 3.MOZHI:                                                                            ______  
 4.VIZHI: 
       NIRAM:         ______ 
      THANMAI:         ______ 
      PAARVAI:         ______ 
  
              5. SPARISAM:                                VEPPAM                MIDHA VEPPAM             THATPAM 
                    OTHERS ________________________________ 
    
           NORMAL                                       AFFECTED 
 6. MALAM: 
                   NIRAM                                                                                                                     ______                                                                                                
      NURAI                                                                                                              ______                
                   IRUGAL / ILAGAL                                                                      ______ 
      EDAI                                                                              ______ 
    
 7. MOOTHIRAM: 
      NEERKURI: 
      NIRAM:                                                            ______ 
        NURAI:                            ______ 
        MANAM:                                                                    ______  
        ENJAL:                                                                                                                  ______ 
        EDAI:                                                                                                                     ______ 
 
    NEIKURI: 
     SERPENTINE FASHION                                         
     ANNULAR/RINGED FASHION                              
     PEARL BEADED FASHION                              
       MIXED FASHION                                              
 
1. NAADI:  
 
 THANI NADI:                VALI                          AZHAL                                       IYAM  
 
 THONTHANADI:      VALI AZHAL            AZHAL VALI              AZHAL IYAM     
             IYA AZHAL        
  
 MUKKUTRANADI          
 
             THODANADI :             VALI IYAM                        IYA VALI   
 
 
SIGNATURE OF INVESTIGATOR:   
SIGNATURE OF LECTURER:    
DATE: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
NATIONAL INSTITUTE OF SIDDHA, CHENNAI-47. 
AYOTHIDOSS PANDITHAR HOSPITAL 
DEPARTMENT OF KUZHANDHAI MARUTHUVAM 
A STUDY ON VIRANA SILETHUMAM (ACUTE PHARYNGO-TONSILLITIS) 
 IN CHILDREN 
FORM V - LAB PARAMETERS CHART 
 
1. SI NO:____ 2 OP /IP NO:_________ 3. NAME: _____________ 4 . AGE: ___5.GENDER: M  F   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
DATE: 
SIGNATURE OF INVESTIGATOR:    
SIGNATURE OF LECTURER: 
 
 
 
 
 
 
ROUTINE BLOOD 
INVESTIGATIONS 
NORMAL 
VALUES 
 
BEFORE 
TMT 
 
 
AFTER 
TMT 
 
Hb ( gms%)  11.5  14.5    
T.RBC (milli /cu.mm)        4-4.9   
 
ESR (mm) 
½ hr. -   
1 hr.        0-13   
T.WBC (milli /cu.mm)    5000-14500   
DIFFERENTIAL 
COUNT (%) 
Polymorphs 40-75   
Lymphocytes 28-48   
Monocytes 3-6   
Eosinophils 0-3   
Basophils 0-1   
ASO     
CRP    
URINE 
INVESTIGATION 
 
   Before TMT 
 
 
   After TMT  
 
Albumin   
Deposits   
NATIONAL INSTITUTE OF SIDDHA, CHENNAI-47. 
AYOTHIDOSS PANDITHAR HOSPITAL 
DEPARTMENT OF KUZHANDHAI MARUTHUVAM 
  A STUDY ON VIRANA SILETHUMAM (ACUTE PHARYNGO-TONSILLITIS) 
 IN CHILDREN 
FORM IV - CLINICAL ASSESSMENT FORM  
 
1. SI NO:____ 2 OP /IP NO:_________ 3. NAME: _____________ 4 . AGE: ___5.GENDER: M  F  
6. DATE OF ADMISSION TO THE TRIAL:        
7. CLINICAL ASSESSMENT: 
      1st day      8th day     14th day 
TEMPERATURE(°F)       
PULSE RATE (per 
min) 
   
HEART RATE (per 
min) 
   
RESPIRATORYRATE 
(per min) 
   
 
COUGH 
   
 
FEVER 
   
 
MALAISE 
   
 
SORE THROAT 
   
DIFFICULTY TO 
SWALLOW 
   
HEADACHE    
ANT CERVICAL 
LYMPHADENITIS 
   
DIFFUSE MUCOSAL 
CONGESTION *** 
   
 
INFLAMMATORY 
EXUDATES 
   
 
PETECHIAE 
   
 
PUSTULES 
   
TONSILLAR 
HYPERTROPHY 
   
 
*** Of palate, faucial pillars, tonsil, posterior pharyngeal wall. 
 
SIGNATURE OF INVESTIGATOR:   
SIGNATURE OF LECTURER: 
 
 
NATIONAL INSTITUTE OF SIDDHA, CHENNAI-47. 
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DEPARTMENT OF KUZHANDHAI MARUTHUVAM 
A STUDY ON VIRANA SILETHUMAM (ACUTE PHARYNGO-TONSILLITIS) 
 IN CHILDREN 
FORM VII - WITHDRAWAL FORM 
 
1. SI NO:____ 2 OP /IP NO:_________ 3. NAME: _____________ 4. AGE: __ 5.GENDER: M  F   
6. POSTAL ADDRESS: __________________________________________________________________ 
______________________________________________________________________________________ 
7. DATE OF ADMISSION TO TRIAL:                        
8. DATE OF WITHDRAWAL FROM TRIAL:             
 
9. REASONS FOR WITHDRAWAL:    
 LONG ABSENCE AT REPORTING                      
 IRRREGULAR TREATMENT         
 SHIFT OF LOCALITY          
 INCREASE IN SEVERITY OF SYMPTOMS       
 DEVELOPMENT OF ADVERSE DRUG REACTIONS      
 ANY OTHER ___________________________________________________________________ 
 
10.CURRENT STATUS OF THE PATIENT: 
______________________________________________________________________________________
______________________________________________________________________________________ 
 
 
 
DATE:  
SIGNATURE OF  INVESTIGATOR:    
SIGNATURE OF LECTURER: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  NATIONAL INSTITUTE OF SIDDHA, CHENNAI-47. 
AYOTHIDOSS PANDITHAR HOSPITAL 
DEPARTMENT OF KUZHANDHAI MARUTHUVAM 
 
A STUDY ON VIRANA SILETHUMAM (ACUTE PHARYNGO-TONSILLITIS) 
 IN CHILDREN 
FORM IX- DRUG COMPLIANCE FORM 
 
 
1. SI NO:____ 2 OP /IP NO:_________ 3. NAME: _____________ 4 . AGE: ___ 5.GENDER: M  F  
NAME OF THE DRUG: MALLI  CHOORANAM. 
FORM OF THE DRUG: POWDER  
ADMINISTRATION & ADJUVANT: PER ORAL, IN MILK 
DOSE & DURATION: 1.5-2.5gms, TWICE DAILY FOR 7 DAYS  
NO. OF DRUG PACKETS GIVEN:      
NO. OF DRUG PACKETS RETURNED:    
 
  
 
SIGNATURE OF  INVESTIGATOR:    
SIGNATURE OF LECTURER: 
DATE: 
 
 
 
 
DAY 
 
       DATE OF          
DRUG    INTAKE 
 
MORNING 
  
 
 EVENING  
  
   
 
DAY 1 
  
    
 
 
DAY2 
   
 
DAY 3 
   
 
DAY 4 
   
 
DAY 5 
   
 
DAY 6 
   
 
DAY 7 
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A STUDY ON VIRANA SILETHUMAM (ACUTE PHARYNGO-TONSILLITIS) 
 IN CHILDREN 
FORM VIII - ADVERSE REACTION (PHARMACO-VIGILANCE) FORM 
 
 
1. SI NO: ____ 2 OP /IP NO: _________ 3. NAME: _____________ 4. AGE: ____ 5.GENDER M  F  
6.Date of trial commencement:                        
7.Date of occurrence of adverse reaction :       
8.Description of adverse reaction: 
 
 
 
 
 
 
SIGNATURE OF  INVESTIGATOR:    
SIGNATURE OF LECTURER: 
DATE:  
 
 
 
 
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Å¢Ã½ º¢§ÄòÐÁõ ±ýÛõ ¦¾¡ñ¨¼ §¿¡öì¸¡É º¢ò¾ ÁÕóÐ ÁøÄ¢                            
ÝÃ½õ ÀÃ¢¸Ã¢ôÒò¾¢È¨Éì ¸ñ¼Ã¢Ôõ ÁÕòÐÅ ¬öÅ¢ü¸¡É  
 
¾¸Åø ÀÊÅõ: 
  
Ó¾ý¨Á ¬Ã¡öîº¢Â¡ª÷: ÁÕ.«.§ÃÏ¸¡ 
¿¢ÚÅÉò¾¢ý ¦ÀÂ÷:§¾º¢Â º¢ò¾ ÁÕòÐÅ ¿¢ÚÅÉõ, 
         ¦ºý¨É-47 
     ´Õ ÅÕ¼ ¸¡Äõ §Áü¦¸¡ûÙõ ­ó¾ ¬öÅ¢ø 40 §¿¡Â¡ª¢¸û 
§¾÷ó¦¾Îì¸ôÀðÎ 7 ¿¡ð¸û º¢¸¢î¨ºìÌ ¯ðÀÎò¾ôÀÎÅ¡÷¸û. ­õÁÕóÐ 3 
Ó¾ø 7 ÅÂÐûª ÌÆó¨¾¸ÙìÌ 1.5¸¢ ÁüÚõ 8 Ó¾ø 12 ÅÂÐûª 
ÌÆó¨¾¸ÙìÌ 2.5¸¢ ¾¢Éõ ­Õ§Å¨ª «ªÅ¡¸ ¾ÃôÀÎõ. 
 
      ­ó¾ ÁÕòÐÅ ¬öÅ¢ü¸¡¸ ¸ð¼½õ ±Ð×õ ÅÝÄ¢ì¸ôÀ¼Á¡ð¼¡Ð.  
­ó¾ ¬öÅ¢ý ãÄõ §¿¡Â¡ª¢ìÌ ±ùÅ¢¾ À¡¾¢ôÒõ ²üÀ¼¡Ð. §¿¡Â¡ª¢¨Â 
ÀüÈ¢Â ÌÈ¢ôÒ¸û Ã¸º¢ÂÁ¡¸ ÀÃ¡ÁÃ¢ì¸ÀÎõ. 
 
  ­ó¾ ¬öÅ¢ý §À¡Ð §¿¡Â¡ª¢ìÌ §ÅÚ À¡¾¢ôÒ¸û ²üÀÎõ Àðºò¾¢ø §¾º¢Â 
º¢ò¾ ÁÕòÐÅÁ¨ÉÂ¢ø ¾ì¸ º¢¸¢î¨º «ª¢ì¸ôÀÎõ. ­õÁÕóÐ Å¢Ã½ 
º¢§ÄòÐÁõ ±ýÛõ ¦¾¡ñ¨¼ §¿¡öì¸¡¸ ãÄ¢¨¸ ¦À¡Õð¸ª¡ø 
¾Â¡Ã¢ì¸ôÀÎÅ¾¡Öõ, ¦¾¡¼÷óÐ ÀÂýÀÎò¾ôÀðÎ ÅÕÅ¾¡Öõ ­õÁÕó¾¢É¡ø 
§ÅÚ À¡¾¢ôÒ ²üÀ¼¡Ð. ­ó¾ ¬öÅ¢ø §¿¡Â¢ÉÃ¡¸ §º÷ó¾ À¢ÈÌõ Å¢ÕôÀõ 
­ø¨Ä¦ÂÉ¢ø ±ô§À¡Ð §ÅñÎÁ¡É¡Öõ Å¢Ä¸¢ì ¦¸¡ûªÄ¡õ. 
 
 «¾ü¸¡É ­ó¾ ¬Ã¡öîº¢ ºõÀó¾Á¡É ÁüÈ Å¢ÀÃí¸ÙìÌ Ó¾ý¨Á 
¬Ã¡öîº¢Â¡ªÃ¡É ÁÕ.«.§ÃÏ¸¡¨Å 9894765816 ±ýÈ ±ñ½¢ø ¦¾¡¼÷Ò 
¦¸¡ûªÄ¡õ. 
 
º¢¸¢îº¡ ÃòÉ ¾£Àò¾¢ø ÜÈôÀðÎûª ÝÃ½ò¾¢ø ÁøÄ¢, ¸¢Ã¡õÒ, ²Äõ Ó¾Ä¢Â 
¸À §¿¡ö ¿¢Å¡Ã½ ¦À¡Õð¸û §º÷ì¸ôÀðÎ §¾º¢Â º¢ò¾ ÁÕòÐÅ 
¬ö×Ü¼ò¾¢ø §¿÷ò¾¢Â¡¸ ÓÊì¸ôÀð¼Ð. ¾í¸ªÐ Å¢ÕôÀò¾¢ý §ÀÃ¢ø 
ÌÆó¨¾¨Â ¬ö×ìÌ ¯ðÀÎòÐõ Àðºò¾¢ø ­¾Û¼ý ­¨½ì¸ôÀÎõ ´ôÒ¾ø 
ÀÊÅò¾¢ø ¾í¸û ¨¸¦ÂØòÐ ¦ÀÈôÀÎõ. 
 
 
 
   
 
 
INFORMATION SHEET regarding the clinical research of the therapeutic 
benefits of Siddha drug MALLI CHOORANAM in treating VIRANA 
SILETHUMAM. 
 
 Principal investigator: Dr.A.RENUGA 
 Place of study: National Institute of Siddha, 
  Chennai-47. 
 
          In this 1 year study, 40 patients are to be treated for 7 days. The drug would 
be dispensed to the patients in doses of 1.5gms (3-7years of age) and 2.5gms  (in 
8-12 years of age). 
 
Through this study a safe, cost effective and reliable drug for throat infection can 
be made known to the world. There will be no risk of physical, psychological or 
professional means, by taking part in this study. Information of your son/daughter 
will be kept confidential. 
 
In the event of development of any other illness, he/she will be treated in 
OPD/IPD of the hospital. The herbal medicine will not cause any risk to his/her 
life or health condition. You can wish not to take part or withdraw from the study 
at any time out of your own free will.  
 
If you agree to make your son/daughter a participant in the study, blood (2ml) and 
urine investigations will be carried out on the before and after treatment to monitor 
health status. The medicine and investigations are free of cost. 
 
If you wish to find out more about this study, you can contact Dr.A.RENUGA,,PG 
Scholar cum Principal Investigator of the study through mobile number 
9894765816. 
 
The drug  MALLI CHOORANAM as stated in Chickicha ratna deepam, consists 
of coriander seeds, clove, elaichi and other ingredients with the property of healing 
throat infections. 
 
Your son/daughter will be made a participant in this study, primarily after you sign 
the consent form on account of wishing to enroll him/her. 
 
 
 
 
ANNEXURE-3 
 
PREPARATION OF TRIAL MEDICINE 
Malli Chooranam  
INGREDIENTS: 
1. Parangi chakkai (smilax china)   
2. Athimathuram (Glycyrrhiza glabra)  
3. Karunseeragam (Nigella sativa)  
4. Seeragam (Cuminum cyminum)  
5. Pilapu seeragam Shah-zirah (Carum bulbocastum)  
6. Elam (Elettaria cardomomum)  
7. Sannalavanga pattai (Cinnamomum verum )  
8. Kirambu (Syzygium aromaticum ) 
9. Viraiilla thiraichai (Vitis vinifera )  
10. Thania (Coriandrum sativum)  
Ref: Chikicha ratna deepam ,Pg.no. 120 
Method of preparation: 
        All the raw drugs given above except coriander seed are fried until to  golden brown 
colour.   Then the drugs are ground into a fine powder. It is filtered by using a fine cloth 
(Vasthirakaayam). Now equal amount of sweet candy powder is added with the 
chooranam and stored in air tight container. 
DOSE :  Arai thola ( 6gms ) 
 1.5 grams  for 3 to 7 years of age, twice daily 
 2.5 grams for 8 to 12 years of age, twice daily  
ADJUVANT:   Milk 
DRUG DURATION: 7 days  
INDICATIONS: Thondaipun, , Thondaikammal, Vikkal, Vaanthi, Kaatthadaippu  
                              Arosikam, Athika viyarvai viduthal, Kaikaal erichal. 
 Coriandrum sativum 
 
Syzygium aromaticum 
 
 
Cinnamomum verum 
Elettaria cardomomum 
 
Cuminum cyminum 
 
Carum bulbocastum 
 Nigella sativa 
 
              
Smilax china 
 
 
 
Glycyrrhiza glabra 
 
Vitis vinifera 
 
NATIONAL INSTITUTE OF SIDDHA 
ACUTE TOXICITY STUDY OF MALLI CHOORANAM 
[WHO guidelines, 1993] 
Principle: 
    Acute toxicity was carried out in Swiss albino mice with a single exposure of 
10 times of the recommended therapeutic dose of test compound the study duration will be 14 
days. 
Animal species  : Swiss albino mice 
Age / Weight / Size  :  6 weeks.  Mice-20-25 gms. 
Gender   :   Both male and female 
Number of Animals   : Mice: 10 
Acclimatization Period : 7 Days 
Clinical dose   : 5.0 gms\day 
 
S.No Group No of mice 
1 Vehicle control (saline) 10  (5 male, 5 female) 
 
2 
Toxic dose 
10X therapeutic dose 
(54mg) 
10  (5 male, 5 female) 
 
Test Animals  
       Test animals were obtained from the animal laboratory of the King institute, 
Chennai and stocked at National institute of siddha, Chennai. All the animals were kept under 
standard environmental condition (27+ or 2 degree c).The animals had free access to water 
and standard pellet diet (Sai Durga foods pvt.ltd, Bangalore).The principles of laboratory 
animal care were followed and the  Institutional ethical committee approved the use of 
animals and the study design. (1248/ac/09/CPCSEA/February/ 2012) 
 Route of administration: 
  Oral route was selected, because it is the normal route of clinical 
administration. 
Test substance and vehicle 
        Malli Chooranam is light greenish yellow in colour.  The test substance is 
insoluble in water, in order to obtain and ensure the uniformity in drug distribution the drug is 
dissolved by aqueous Tween 80 solution (30%).  
Administration of doses 
            Malli Chooranam  was suspended in aqueous Tween 80 solution (30%), with 
uniform mixing and it was administered to the groups in a single oral dose .The control 
groups were received equal volume of the vehicle. The animals were weighed before giving 
the drug. The dose level was calculated according to body weight, and surface area. Since the 
clinical dose was 3.0gms\day it was converted to animal dose (54mg) and then administered. 
The principle of laboratory animal care was followed. 
Observations 
  Observations were made and recorded systematically and continuously 
observed as per the guideline after substance administration. The animals were monitored for 
behavioural parameters like 
1. Awareness 
- Alertness 
- Visual placing 
- Stereotype 
- Passivity 
-  
2. Mood 
-  Grooming 
-  Restlessness 
-  Irritability 
-  Fearfulness 
3. Motor activity 
- Spontaneous activity 
- Reactivity 
- Touch response 
- Pain response.  
Animals were observed for body weight and mortality for 14 days. If animals died 
during the period of study, the animals were sacrificed.  At the end of the 14th day all animals 
were sacrificed and necropsy was done. 
Body Weight 
  Individual weight of animals was determined before the test substance was 
administered and daily for 14 days. Weight changes were calculated and recorded. At the end 
of the test, surving animals were weighed and sacrificed. 
Results:   
Malli Chooranam at the dose 54mg/animal did not exhibit any mortality in mice. 
  No behavior changes were noted for the first 4 hours and for the next 24 hours 
and throughout the study period of 14 days. No weight reduction was noted before and after 
the acute study duration. Reflexes were found to be normal before and after the study. All 
other observations were found to be normal before and after the study. In Necropsy, the 
organs of the animal such as, Liver, Heart, Lungs, Pancreas, Spleen, Stomach, Intestine, 
Kidney, Urinary bladder, Uterus all appeared normal. 
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